Index

Note: Page numbers in italics refer to figures; page numbers inbold refer to tables

Abelson 1 breakapart cluster fusion gene, 508 case study, 378, 391, 391–392 phenotypic studies, 283–284, 286, 287, 288, acitretin, 18 pathology, 381, 391, 392 289 acquired immunodeficiency syndrome (AIDS), alemtuzumab post-transplant, 281, 288–289, 288–289, 301, plasmablastic lymphoma, 427, 427 cutaneous T cell lymphoma, 18 302, 303, 303–304, 419 acral pseudolymphomatous angiokeratomas of Sézary syndrome, 18 primary, 281 children (APACHE), 67 T cell prolymphocytic leukemia, 453 pyogenic, 282 ACT-1 see CD25 antigen aleukemic leukemia cutis, 507 sarcomatoid see sarcomatoid anaplastic large actinic dermatitis, chronic, 52 ALK see anaplastic lymphoma kinase (ALK) cell lymphoma actinic prurigo, 52 ALK-1 breakapart probe, 13 secondary, 281 actinic reticuloid, 52, 356 allergic contact dermatitis, 37–39 small cell see small cell anaplastic large cell activation/proliferation markers clinical features, 37, 38 lymphoma anaplastic large cell lymphoma, 283 differential diagnosis, 39 type I cells, 281, 287, 288 definitions, 12 histomorphology, 37 type II cells, 281, 289, 297 acute monoblastic and monocytic leukemia, 535 pathogenesis, 39 unusual histologic variants, 282 acute monoblastic leukemia, 508, 513 allogeneic bone marrow transplant variants/subtypes, 280, 280 acute monocytic leukemia, 509 acute graft-versus-host disease, 44 anaplastic lymphoma kinase (ALK) acute myelogenous leukemia, 508 subcutaneous panniculitis-like T cell anaplastic large cell lymphoma, 280, 282, 283, case studies, 517, 517 lymphoma, 336 286 light microscopic findings, 509 allogeneic hematopoietic stem cell detection methods, 284 subtypes, 507, 534, 535 transplantation (allo-HSCT), cutaneous T lymphomatoid papulosis, 277, 281 acute myeloid leukemia, 509, 534 cell lymphoma, 20 rearrangement, 308 acute myelomonocytic leukemia, 535 alopecia, syringolymphoid hyperplasia with anaplastic lymphoma kine-positive diffuse large acute promyelocytic leukemia (APL), 534, 535 see syringolymphoid hyperplasia with B cell lymphoma, 283 adipocyte rimming alopecia anaplastic plasmacytoma see plasmablastic γ δ T cell lymphoma, 407, 410, 411 alopecia mucinosa, 98, 98–99 lymphoma subcutaneous panniculitis-like T cell case studies, 111–114, 111–114, 115, 117, 117 angiocentric cutaneous T cell lymphoma of lymphoma, 336, 343, 346 differential diagnosis, 98, 99 childhood, 416 adnexotropic mycosis fungoides, 240–241, 250, follicular mycosis fungoides, 240 angiocentric immunoproliferative lesions (AIL), 253 light microscopic findings, 99,111, 113, 117 499 adnexotropic T cell dyscrasia, case study, 115, molecular studies, 99, 114, 116, 126 angiocentric T cell lymphoma, differential 115–116 phenotypic studies, 99, 112, 113, 114 diagnosis, 501 adult T cell leukemia/lymphoma, 473, 473–485 amyloidosis, nodular, 143 angioimmunoblastic lymphadenopathy with acute, 473, 473–475, 474, 479–480, 479–481 anaplastic large cell lymphoma, 280, 280–282, dysproteinemia see angioimmunoblastic T case studies, 477–483, 477–483 281 cell lymphoma chronic, 474, 474 activation antigens, 283 angioimmunoblastic T cell lymphoma, 486, clinical features, 473, 473–474 breast-implant-associated, 282 486–498, 489 differential diagnosis, 454, 474 case studies, 33, 33, 286–289, 286–289 architectural growth patterns, 487 follicular mucinosis, 475 categorization, 281 autoimmune diathesis, 486 HTLV-1-associated post-transplant, 419COPYRIGHTEDCD8-positive MATERIALcase studies, 491–496, 491–496 immune suppression, 474 case study, 297, 297 clinical features, 486, 486–487 lymphomatous, 473, 474, 482, 482, 483 phenotypic studies, 283, 284, 293, 294, 295, composite lymphoma, 487 pathogenesis, 475–476 297 differential diagnosis, 487 pathology, 474–475, 477, 479, 480 cytogenetics, 284, 302 diffuse large B cell lymphoma, 487 phenotypic studies, 475, 478 differential diagnosis, 316, 319, 437, 513 drug-induced, 486 prognosis, 474 intravascular, 219–220, 282–283 Epstein–Barr virus, 486–487, 488, 489 skin lesions, 474 light microscopic findings, 281–282,286, 287, light microscopic findings, 487, 492, 495 smoldering, 474, 474, 477, 477, 478 288, 289 lymph node changes, 487, 491, 495 treatment, 475 lymphomatoid papulosis vs., 280 molecular studies, 488–489 236A/F7 see Fox P3 molecular studies, 301 pathogenesis, 489–490 aggressive natural killer cell lymphoma, 378, myxoid, 283, 305, 305, 306 phenotypic studies, 488, 491 380, 380, 391 pathogenesis, 284–285 primary cutaneous B cell lymphoma, 487

The Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin, Second Edition. Cynthia M. Magro, A. Neil Crowson and Martin C. Mihm. © 2016 John Wiley & Sons, Inc. Published 2016 by John Wiley & Sons, Inc.

541

bindex 541 19 November 2015 7:21 PM 279mm×216mm 542 Index angioimmunoblastic T cell (continued) bax, mycosis fungoides, 257 Berti’s lymphoma see primary cutaneous B cell(s) aggressive epidermotropic cytotoxic skin findings, 487, 491, 494 clonality assessment, 28 CD8+ T cell lymphoma therapy, 486 differentiation stage, 138 beta 1 integrin subunit see CD29 antigen vascular changes, 487, 494 lymphocytoma cutis, 66 bexarotene angioinvasion marginal zone lymphoma, 136, 145 adverse events, 17 γ δ T cell lymphoma, 409 paraffin-embedded tissue panels, 12 cutaneous T cell lymphoma, 15–16, 17 nasal natural killer cell/T cell lymphoma, 388 proliferation, 138 denileukin diftitox and, 17–18 type E lymphomatoid papulosis, 276, 278 V-D-J rearrangement, 23 mycosis fungoides, 15–16 angiolymphoid hyperplasia with eosinophilia B cell chronic lymphocytic leukemia (B-CLL), safety/efficacy, 16 (ALHE), 67–68 449–452, 450, 469 BF-1 antibody angiotropism, 169 case studies, 455–461, 455–461 definition, 9 γ δ T cell lymphoma, 407, 409 clinical features, 449–450 γ δ T cell lymphoma, 408, 411 annular lichenoid dermatosis of youth, 92 cytogenetics, 451, 467 Binet staging system, chronic lymphocytic antibodies, 13 molecular studies, 451 leukemia, 449 antibody drug conjugates (ADC), 19 morphology, 450, 455, 456, 457, 458, 459, 460, Birbeck granules, Langerhans sarcoma, 512 antihistamines 461 blastic marginal zone lymphoma, 140, 161, 162, marginal zone lymphoma, 134 pathogenesis, 452 188, 189, 194–195 reactive lymphoid hyperplasia induction, 134 phenotype, 451, 457, 459, 461 case study, 161, 161–163 antiphospholipid antibody syndrome, 45 prognosis, 450, 451 cytogenetic profile, 163, 194 anti-Ro-associated systemic lupus B cell hyperplasia de novo, 140, 194 erythematosus, 46 mycosis fungoides, 251 light microscopic findings, 140, 226, 229, 232 clinical features, 49 primary cutaneous CD4+ small/medium- phenotypic profile, 140 histopathology, 50 sized pleomorphic T cell lymphoma, 317 prognosis, 194 immunofluorescent findings, 50 B-cell lymphoid hyperplasia, 138 reactive germinal centers, 190 antithymocyte autoantibody, chronic B cell markers, definition, 10–11 subtypes, 140, 194 lymphocytic leukemia, 452 B cell neoplasms, classification, 138 blastic NK cell lymphoma see blastic antivirals, post-transplant lymphoproliferative bcl-1 plasmacytoid dendritic cell neoplasm disease, 418 blastoid mantle cell lymphoma, 230, 232 blastic NK-like T cell lymphoma see blastic API2 MALT1 fusion probe, 13 definition, 10 plasmacytoid dendritic cell neoplasm API2-MALT1 fusion protein, marginal zone mantle cell lymphoma, 226, 227, 233 blastic plasmacytoid dendritic cell neoplasm, lymphoma, 138 bcl-2 377, 379, 382–383, 383, 507, 510 apoptosis blastic marginal zone lymphoma, 162, 195 case study, 399, 399–400 acute graft-versus-host disease, 45 chronic lymphocytic leukemia, 451 light microscopic findings, 383 CD10 antigen, 196, 488 definition, 10 molecular studies, 383 mycosis fungoides, 257 diffuse large B cell lymphoma, leg type, 190, phenotypic studies, 383, 399, 400 systems, 257 202 blastoid mantle cell lymphoma, 226 apoptosis regulator B cell lymphoma 10 (BCL10) double-hit lymphoma, 197 case studies, 229, 229, 230, 232, 232 see Bcl-10 marginal zone lymphoma, 137, 150 cytogenetic studies, 233 APRIL, chronic lymphocytic leukemia, 451 precursor B cell lymphoblastic lymphoma, 212 BLIPM-1, diffuse large B cell lymphoma, leg arthropod-bite responses, 39 primary cutaneous follicle center lymphoma, type, 193 ataxia telangiectasia, 453 171, 172–173, 175, 183 BOB-1, lymphocyte-predominant Hodgkin ataxia telangiectasia mutated gene/protein bcl-2 IgH fusion probe, 13, 195 lymphoma, 437 (ATM) bcl-6 body-surface area (BSA) mantle cell lymphoma, 227, 228 definition, 10 calculation, 4, 245 T cell prolymphocytic leukemia, 454 diffuse large B cell lymphoma, 190 mycosis fungoides, 4, 236 atopic dermatitis, 41, 242, 244 diffuse large B cell lymphoma, leg type, 193 bone marrow erythrodermic, 244 follicular helper T cell lymphoma, 317 mycosis fungoides, 254 atypical fibroxanthoma, 515 Hodgkin lymphoma, 437, 442 myelodysplastic syndrome, 508 atypical lymphocytic lobular panniculitis, 100, marginal zone lymphoma, 137 bone marrow biopsy, 5 100–101, 101, 336, 337–338 primary cutaneous follicle center lymphoma, borderline CD30-positive lymphoproliferative case studies, 109, 109–110, 118, 118, 345, 173, 180, 183, 190, 191, 193, 204 disorders, 279, 290, 290, 291, 296 345–346 BCL7a, mycosis fungoides, 258 Borrelia burgdorferi differential diagnosis, 101, 337–338, 408 Bcl-10 marginal zone lymphoma, 138 light microscopic findings, 101,107–108, 109, 118 definition, 10 morphea, 55 molecular studies, 101, 127, 129 marginal zone lymphoma, 137 BRAF mutation, Langerhans cell histiocytosis, morphology, 338 BDCA-1 511 pathology, 338, 345–346 cutaneous myeloid dendritic cell dyscrasia, 513 breast-implant-associated anaplastic large cell phenotypic studies, 101, 109, 110 myeloid dendritic cells, 509 lymphoma, 282 autoeczematization (id reaction), 39–40, 65 BDCA2 see CD303 brentuximab vedotin, 19 autoimmune progesterone dermatitis, 43 “bean bag histocyte,” 336 bupropion, marginal zone lymphoma induction, autoreactive T cell clones, chronic graft-versus- Bence–Jones protein, metastatic plasmacytoma, 138 host disease, 51 143 Burkitt’s lymphoma, 198 benign lymphocytic infiltrates, 37–58 B1 see CD20 antigen pathogenesis, 37 C5.9 see CD56 markers baboon syndrome, 39 Ber-H2 see CD30 antigen 4C7 see CD5 antigen basal cell carcinoma, 460, 460 Ber-T9, 12 C8/144B see CD8 antigen

bindex 542 19 November 2015 7:21 PM 279mm×216mm Index 543

CALLA see CD10 Hodgkin lymphoma, 442 blastic marginal zone lymphoma, 140, 190, Campath-1H see alemtuzumab intravascular lymphoma, 222 194 capillary electrophoresis technique, 25 keratoderma-like T cell dyscrasia, 100, 131 blastoid mantle cell lymphoma, 230, 232 T cell dyscrasias, 27 large plaque parapsoriasis, 90 B lymphocytes, 452 cardiovascular system, mycosis fungoides, 254 marginal zone lymphoma, 136, 145, 155 chronic lymphocytic leukemia, 451 carmustine (BCNU), mycosis fungoides, 15 nasal natural killer cell/T cell lymphoma, 389 definition, 9 Castleman disease, 66, 141–142 nasal type natural killer cell/T cell lymphoma, indolent CD8 positive lymphoid proliferation case studies, 159, 159, 164, 164–165 398 of the face, 355, 373 differential diagnosis, 142 natural killer cells, 378 intravascular lymphoma, 219 epidemiology, 142 natural killer cell/T cell lymphoma, 377, 381, large plaque parapsoriasis, 90 idiopathic plasmacellular lymphadenopathy, 385, 396 mantle cell lymphoma, 226 66 primary cutaneous aggressive marginal zone lymphoma, 137 light microscopic findings, 141–142, 159, 164 epidermotropic cytotoxic CD8+ T cell mycosis fungoides, 255, 255 mixed variant, 141, 160 lymphoma, 358 primary cutaneous CD4+ small/medium- multicentric, 66, 141, 164 primary cutaneous follicle center lymphoma, sized pleomorphic T cell lymphoma, 316, nonidiopathic plasmacellular 180, 184 323 lymphadenopathy, 66 subcutaneous panniculitis-like T cell subcutaneous panniculitis-like T cell pathogenesis, 142 lymphoma, 337, 341 lymphoma, 337, 344 phenotyping, 142 Cd3 receptor see CD21 CD7 antigen plasma cell variant, 141 CD4 antigen adult T cell leukemia/lymphoma, 475, 478 subcutaneous, 159, 159 acute graft-versus-host disease, 45 alopecia mucinosa, 112, 114 therapy, 142 adult T cell leukemia/lymphoma, 475, 478 angioimmunoblastic T cell lymphoma, 488, CCL4, adult T cell leukemia/lymphoma, 475 anaplastic large cell lymphoma, post- 491 CCL5 transplant, 289 atypical lymphocytic lobular panniculitis, 101, γ δ T cell lymphoma, 407, 410, 412 angioimmunoblastic T cell lymphoma, 488, 109, 346 lupus erythematosus profundus, 64 491 cutaneous lymphoid dyscrasia, 89 subcutaneous panniculitis-like T cell blastic plasmacytoid dendritic cell neoplasm, definition, 9 lymphoma, 337, 347 383, 400 granulomatous mycosis fungoides, 269 CCND2, mantle cell lymphoma, 227 cutaneous myeloid dendritic cell dyscrasia, HIV-related CD8 pseudolymphoma, 356, 369 CCR4 531 indolent CD8 positive lymphoid proliferation allergic contact dermatitis, 258 definition, 9 of the face, 373 cutaneous T cell lymphoma, 14 histiocytic sarcoma, 515 keratoderma-like T cell dyscrasia, 99–100, 131 mycosis fungoides, 258 Langerhans sarcoma, 512, 523 large plaque parapsoriasis, 90 CCR5, subcutaneous panniculitis-like T cell large plaque parapsoriasis, 90 lymphocytoma cutis, 78 lymphoma, 337, 347 lymphomatoid drug eruptions, 62, 73 lymphomatoid drug eruptions, 61, 62, 73 CCR10 mycosis fungoides, 255 mycosis fungoides, 254–255, 255 atopic eczema, 244, 258 natural killer-like CD4+ T cell lymphoma, pigmented purpuric dermatosis, 94, 106 mycosis fungoides, 244, 258 384, 385, 394, 396 pityriasis lichenoides chronica, 95, 104 Sézary syndrome, 244 pityriasis lichenoides chronica, 95, 104 primary cutaneous aggressive epidermotropic CD1a antigen primary cutaneous CD4+ small/medium- cytotoxic CD8+ T cell lymphoma, 354, definition, 9 sized pleomorphic T cell lymphoma, 330 359 indeterminate cell proliferative disorder, subcutaneous panniculitis-like T cell primary cutaneous CD4+ small/medium- 511–512, 521 lymphoma, 337, 344 sized pleomorphic T cell lymphoma, 316, Langerhans cell histiocytosis, 511 T cell prolymphocytic leukemia, 464, 465 321, 323 Langerhans sarcoma, 512, 523 type C lymphomatoid papulosis, 296 reversible drug-associated T cell dyscrasia, 61 CD1d antigen, 404 CD4/CD8 ratio subcutaneous panniculitis-like T cell chronic lymphocytic leukemia, 451 atypical lymphocytic lobular panniculitis, lymphoma, 337, 342 CD2 antigen 101, 110 T cell prolymphocytic leukemia, 364, 453, 463 adult T cell leukemia/lymphoma, 475, 478 differential diagnosis, 244 vesicular mycosis fungoides, 242, 267 definition, 9 folliculotropic T cell lymphocytosis, 98 CD8 antigen marginal zone lymphoma, 136 granulomatous mycosis fungoides, 269 acute graft-versus-host disease, 45 natural killer-like CD4+ T cell lymphoma, 385 lymphomatoid drug eruptions, 61 aggressive NK cell lymphoma, 391 primary cutaneous aggressive epidermotropic lymphomatoid granulomatosis, 500, 504 blastoid mantle cell lymphoma, 226 cytotoxic CD8+ T cell lymphoma, 354, pityriasis lichenoides chronica, 104 CD8-positive anaplastic large cell lymphoma, 358 Sézary syndrome, 244, 245 297 primary cutaneous CD4+ small/medium- vesicular mycosis fungoides, 242, 267 definition, 9 sized pleomorphic T cell lymphoma, 316, CD4+CD28- T cells, 314 granulomatous mycosis fungoides, 242 320, 321 CD4+ CD56+ hematodermic neoplasm see hypopigmented interface T cell dyscrasia, 92 vesicular mycosis fungoides, 267 blastic plasmacytoid dendritic cell indolent CD8 positive lymphoid proliferation CD3 antigen neoplasm of the face, 355 anaplastic large cell lymphoma, 283, 288, 297 CD4/CD56-positive T lymphocytes, 385 lymphomatoid lichen sclerosus, 64 angioimmunoblastic T cell lymphoma, 488, CD4+ natural killer-like T cell lymphoma, 393 lymphomatoid papulosis see lymphomatoid 491, 494 CD5/54/F6 see CD5 antigen papulosis B cell chronic lymphocytic leukemia, 461 CD5 antigen mycosis fungoides, 255, 256 definition, 9 atypical lymphocytic lobular panniculitis, nasal natural killer cell/T cell lymphoma, 390 HIV-associated CD8 pseudolymphoma, 356, 101, 346 pityriasis lichenoides chronica, 95, 104 368 B cell chronic lymphocytic leukemia, 458, 461 pityriasis lichenoides et varioliformis acuta, 95

bindex 543 19 November 2015 7:21 PM 279mm×216mm 544 Index

CD8 antigen (continued) definition, 10 paraffin-embedded tissue panels, 12 diffuse large B cell lymphoma, 190, 201, 204 primary cutaneous aggressive epidermotropic primary cutaneous aggressive epidermotropic double-hit lymphoma, 198 cytotoxic CD8+ T cell lymphoma, 361 cytotoxic CD8+ T cell lymphoma, 359, 362 Epstein–Barr virus+ B cell lymphoproliferative primary cutaneous CD4+ small/medium- primary cutaneous CD4+ small/medium- disease of the elderly, 428 sized pleomorphic T cell lymphoma, 316, sized pleomorphic T cell lymphoma, 330 functions, 354 319, 324, 324, 325, 327, 327 subcutaneous panniculitis-like T cell intravascular lymphoma, 219, 221, 222 primary cutaneous follicle center lymphoma, lymphoma, 337, 342, 344 lymphocyte-predominant Hodgkin 171 CD8+ granulomatous T cell lymphoma, 353 lymphoma, 437 small cell anaplastic large cell lymphoma, 282, CD8-positive cytotoxic T cell lymphoma, 278 lymphocytoma cutis, 66, 71, 78 286 CD8-positive lymphoid proliferation of the face lymphomatoid granulomatosis, 505 viral-associated lymphomatoid dermatitis, 65 (indolent CD8 lymphoid proliferation of marginal zone lymphoma, 136, 137, 147, 149, CD30-negative CD8+ large cell peripheral T cell the ear), 374, 374 155 lymphoma, 354 CD8-positive peripheral T cell lymphomas, 352, mycosis fungoides, 256 CD30-negative large cell T cell lymphoma, 352 precursor B cell lymphoblastic lymphoma, 313–314, 314 CD8-positive pseudolymphoma see 196, 207 case studies, 326, 326, 328, 328 pseudolymphoma primary cutaneous follicle center lymphoma, CD8 positivity, 371, 371 CD8 T cell lymphoproliferative disease of the 175, 177, 180, 184 clinical course, 313–314 skin, 351–376 CD21 antigen histomorphology, 353, 371 case studies, 357–374, 357–374 angioimmunoblastic T cell lymphoma, 487, light microscopic findings, 315, 316, 326 CD10 antigen, 488 488, 493 molecular profile, 318 angioimmunoblastic T cell lymphoma, 488, definition, 11–12 phenotypic studies, 317–318 491 follicular dendritic cell sarcoma, 516 CD30-positive B cell lymphoproliferative apoptosis, 196, 488 marginal zone lymphoma, 136, 148, 150 disease/lymphoma of the elderly, 285 Burkitt’s lymphoma, 196 CD30-positive large B cell lymphoma, 193–194, definition, 10 primary cutaneous follicle center lymphoma, 285 mantle cell lymphoma, 226 171, 175, 177, 181 case study, 298, 298 marginal zone lymphoma, 137, 150 CD22 antigen, definition, 10 differential diagnosis, 285 precursor B cell lymphoblastic lymphoma, CD23 antigen, 137 Epstein–Barr virus-positive, 194 196, 207 B cell chronic lymphocytic leukemia, 457, Hodgkin lymphoma vs., 438 primary cutaneous follicle center cell 458, 461 light microscopic findings, 285, 298, 299 lymphoma, 171, 172, 175, 177, 178, 180, blastic marginal zone lymphoma, 140, 194 phenotypic studies, 285, 298, 299 183, 193 blastoid mantle cell lymphoma, 230 CD30-positive lymphoproliferative disease in primary cutaneous follicle center lymphoma, chronic lymphocytic leukemia, 451 childhood, post-transplant, 419 187, 204 definition, 12 CD30-positive lymphoproliferative disorders, CD11c antigen diffuse large B cell lymphoma, 190 274–311 cutaneous myeloid dendritic cell dyscrasia, follicular dendritic cell sarcoma, 516 case studies, 286–308 528, 531 mantle cell lymphoma, 226 see also individual disorders definition, 11 marginal zone lymphoma, 136, 137, 138, 146, CD30-positive T cell lymphoproliferative indeterminate cell proliferative disorder, 521 147, 155 disorders of CD8 subtype, 354–355 Langerhans cell histiocytosis, 518 primary cutaneous follicle center lymphoma, CD31 antigen, 512 Langerhans cell sarcoma, 523 171, 175, 177, 181 function, 512 myeloid dendritic cells, 509 CD25 antigen indeterminate cell proliferative disorder, 521 CD14 antigen adult T cell leukemia/lymphoma, 483 Langerhans cell histiocytosis, 511, 519 acute myelogenous leukemia, 517 definition, 12 Langerhans sarcoma, 512 cutaneous myeloid dendritic cell dyscrasia, 513 follicular dendritic cell sarcoma, 516 CD34 antigen definition, 11 mycosis fungoides, 256 definition, 11 histiocytic sarcoma, 515, 516 CD26 antigen dendritic cells, 509 CD15 antigen definition, 9 myelodysplastic syndrome, 508 Hodgkin lymphoma, 437, 446 Sézary syndrome, 9 precursor B cell lymphoblastic lymphoma, 196 lymphomatoid papulosis, 279 CD29 antigen CD35 antigen, definition, 12 CD16 antigen intravascular lymphoma, 219, 222 CD38 antigen, chronic lymphocytic leukemia, definition, 10 leukemia cutis, 508 451 natural killer cell/T cell lymphomas, 381 CD30 antigen, 274 CD40 antigen, Hodgkin lymphoma, 442 CD19 antigen anaplastic large cell lymphoma, 287 CD43 antigen chronic lymphocytic leukemia, 451 post-transplant, 288, 289 chronic lymphocytic leukemia, 451 definition, 10 cutaneous T cell lymphoma prognosis, 14 definition, 9, 11 CD20 antigen definition, 12 diffuse large B cell lymphoma, 190, 201, 205 B cell chronic lymphocytic leukemia, 457, diffuse large B cell lymphoma, 190, 419 leg type, 201 458, 461 Epstein–Barr virus+ B cell lymphoproliferative leukemia cutis, 509 blastic marginal zone lymphoma, 162 disease of the elderly, 429 mantle cell lymphoma, 226 blastoid mantle cell lymphoma, 230 Hodgkin lymphoma, 437, 441, 446 marginal zone lymphoma, 149 CD30-negative CD8+ large cell peripheral T lymphomatoid drug eruptions, 61, 62, 75 natural killer-like CD4+ T cell lymphoma, 394 cell lymphoma, 354 lymphomatoid papulosis, 277, 279, 291, 296, primary cutaneous follicle center lymphoma, CD30-positive large B cell lymphoma, 298, 307 171, 172, 205 299 mycosis fungoides, 253, 254, 255, 259 CD44 markers, anaplastic large cell lymphoma, chronic lymphocytic leukemia, 451 natural killer cell/T cell lymphomas, 381–382 284

bindex 544 19 November 2015 7:21 PM 279mm×216mm Index 545

CD45 markers precursor B cell lymphoblastic lymphoma, 196 chemokines, angioimmunoblastic T cell anaplastic large cell lymphoma, 283 CD79a marker, 10 lymphoma, 489 histiocytic sarcoma, 530 blastoid mantle cell lymphoma, 230 chemotherapy leukemia cutis, 509 diffuse large B cell lymphoma, 190, 202, 204 cytotoxic, cutaneous T cell lymphoma, 19–20 lymphocyte-predominant Hodgkin leg type, 202 natural killer cell/T cell lymphomas, 379 lymphoma, 437 intravascular lymphoma, 219 topical, 15 mycosis fungoides, 256 marginal zone lymphoma, 136 chemotherapy-associated acral erythema, 45 CD47 antigen, intravascular lymphoma, 219 primary cutaneous follicle center lymphoma, 2-chlorodeoxyadenosine (2-CDA), 19 CD49d (VLA-4), intravascular lymphoma, 219 177, 204 chromosome 6q deletion CD52 antigen CD83 antigen hydroa vacciniforme-like-EBV adult T cell leukemia/lymphoma, 475 definition, 11 lymphoproliferative disease, 417 paraffin-embedded tissue panels, 12 plasmacytoid dendritic cells, 510 natural killer cell/T cell lymphomas, 382, 398 T cell prolymphocytic leukemia, 453, 466 CD99 antigen, granulocytic sarcoma, 208 peripheral T cell lymphoma, not otherwise CD54 see intercellular adhesion molecule 1 CD103 antigen, mycosis fungoides, 255 specified, 331 (ICAM-1) CD106 (CD49d ligand), intravascular chromosome 7q deletion CD56 markers lymphoma, 219 blastic marginal zone lymphoma, 140, 163, adult T cell leukemia/lymphoma, 475 CD117 marker, definition, 11 195 aggressive natural killer cell lymphoma, 391 CD123 antigen diffuse large B cell lymphoma, 191 blastic plasmacytoid dendritic cell neoplasm, blastic plasmacytoid dendritic cell marginal zone lymphoma, 138 383, 400 neoplasm, 383 chromosome 11 abnormalities, T cell cutaneous myeloid dendritic cell dyscrasia, definition, 11 prolymphocytic leukemia, 454 532 lupus erythematosus profundus, 338 chromosome 11q22.3-923.1 deletion, mantle cell definition, 10 plasmacytoid dendritic cells, 510 lymphoma, 227 γ β T cell lymphoma, 407, 412, 413 CD138 marker, definition, 10 chromosome 13q deletion, chronic lymphocytic hydroa vacciniforme-like lymphoma, 386 CD163 antigen leukemia, 451 natural killer cells, 378 definition, 11 chromosome 14q32.1, adult T cell leukemia/ natural killer cell/T cell lymphomas, 381, 389, histiocytic sarcoma, 515, 516 lymphoma, 475–476 391 myeloid dendritic cells, 509 chromosome 14q inversion, T cell CD4+ subset, 384, 385, 394, 396 CD183 marker, leukemia cutis, 508 prolymphocytic leukemia, 453 nasal, 389, 390 CD279 see Programmed death-1 (PD-1) chromosome 17q deletion, chronic lymphocytic plasmablastic lymphoma, Epstein–Barr virus/ CD303 leukemia, 451 HHV8 associated, 424 lupus erythematosus profundus, 338 chronic granular lymphocytosis see large plasmacytic marginal zone lymphoma, 425 plasmacytoid dendritic cells, 510 granular cell leukemia CD57 antigen, natural killer cell/T cell CDKN2A chronic lymphocytic inflammation with lymphomas, 381 diffuse large B cell lymphoma, 214 pontine perivascular enhancement CD62E selectins, 9 leg type, 191, 193 responsive to steroids (CLIPPERS) CD62L selectins mantle cell lymphoma, 228 syndrome, 66, 502 adult T cell leukemia/lymphoma, 475 mycosis fungoides, large cell transformation, chronic lymphocytic leukemia (CLL) aggressive epidermotropic cytotoxic CD8+ T 254 B cell see B cell chronic lymphocytic leukemia cell lymphoma, 354 CDKN2B, mycosis fungoides, 254 (B-CLL) cutaneous lymphoid dyscrasia, 89 celiac disease, enteropathy-associated mycosis fungoides and, 29, 29, 30, 450, 470, definition, 9 lymphoma, 352, 407 470 folliculotropic T cell lymphocytosis, 98 central nervous system, mycosis fungoides, 254 staging systems, 449 HIV-related CD8 pseudolymphoma, 356 centroblasts T cell see T cell prolymphocytic leukemia keratoderma-like T cell dyscrasia, 99 diffuse large B cell lymphoma, leg type, 193 (T-PLL) large plaque parapsoriasis, 90 marginal zone lymphoma, 137 T cell function abnormalities, 452 lymphocytoma cutis, 78 primary cutaneous follicle center lymphoma, chronic lymphocytic leukemia upregulated gene lymphomatoid drug eruptions, 62 169–170, 174, 176, 182 1 (CLLU), 451 lymphomatoid papulosis, 277 centrocytes chronic myelogenous leukemia, 508 mycosis fungoides, 254–255 marginal zone lymphoma, 137 chronic myelomonocytic leukemia, 508, 509 myeloid leukemia, 508 primary cutaneous follicle center lymphoma, chronic myeloproliferative disease, 508, 513 pigmented purpuric dermatosis, 94 170, 174, 176, 182 monocytosis, 513 pityriasis lichenoides chronica, 95 cerebriform lymphocytes, 73, 76 phenotypic studies, 509 reversible drug-associated T cell dyscrasia, 61 adult T cell leukemia/lymphoma, 474 chronic natural killer cell peripheral blood CD62P selectins, 9 alopecia mucinosa, 111, 117 lymphocytosis, 379 CD68 antigen cutaneous lymphoid dyscrasia, 90, 91, 94, 95 13-cis-retinoic acid see isotretinoin definition, 11 idiopathic follicular mucinosis (alopecia CLA see cutaneous lymphocyte antigen (CLA) indeterminate cell proliferative disorder, 521 mucinosa), 111, 117 classification schemes, lymphoma, 1–8 indolent CD8 positive lymphoid proliferation mycosis fungoides, 247, 248, 248, 250, 252, see also individual classification schemes of the face, 355 316 cleaved follicle center cell see centrocytes interdigitating dendritic cell sarcoma, 516 pigmented purpuric dermatoses, 93, 94, 105 CLIPPERS syndrome, 66, 502 leukemia cutis, 509 pityriasis lichenoides chronica, 91, 95, clonal cutaneous monocytosis see cutaneous myeloid dendritic cells, 509 95, 103 myeloid dendritic cell dyscrasia CD71antigen, definition, 12 primary cutaneous pleomorphic T cell clonal histiocytopathy syndromes, 507, 509–514 CD79 antigen lymphoma, 316, 322 clonality analysis, 23 definition, 10 Sezary syndrome, 247 limitations, 27–28 plasmacytic marginal zone lymphoma, 425 vesicular mycosis fungoides, 242 clones, 13

bindex 545 19 November 2015 7:21 PM 279mm×216mm 546 Index clusterin, anaplastic large cell lymphoma, 284, case studies, 102–131 adult T cell leukemia/lymphoma, 476 437 risk stratification molecular tools, 14 allergic contact dermatitis, 39 c-myc protein/C-MYC gene staging procedures, 14–15 cutaneous T cell lymphoma therapy, 20 natural killer cell/T cell lymphomas, 382 therapy, 14–22 Langerhans cell histiocytosis, 511 T cell prolymphocytic leukemia, 453–454, 465 advanced-stage disease goals, 16 see also individual cytokines collagen, morphea, 55 combination, 15 cytoplasmic tyrosinase kinase gene, precursor B collagen vascular disease investigational, 20 cell lymphoblastic lymphoma, 196, 211 antibody-dependent cellular immunity skin-directed, 14, 15–16 cytotoxic chemotherapy, cutaneous T cell compatible, 45–46 systemic, 14, 16, 17–20 lymphoma, 19–20 antiendothelial-cell antibodies, 45–46 treatment, 19 cytotoxic lymphocytes, 351 γ δ T cell lymphoma, 406 CXCL12 cytotoxic proteins, 351 interface dermatitis, 43 blastic plasmacytoid dendritic cell neoplasm, 383 CD8 positive T cell lymphoma, 351 lymphomatoid tissue response, pathogenesis, mycosis fungoides, 258 cell expressing, 379 63 CXCL13 markers, 10 reactive lymphomatoid lesions, 63–67 angioimmunoblastic T cell lymphoma, 488 natural killer cells, 379 colony-stimulating factor 2 receptor α chain follicular helper T cell lymphoma, 317 natural killer-like cells, 379 (CSF2RA), 11 CXCR3 paraffin-embedded tissue panels, 12 combined WHO/EORTC classification see cutaneous T cell lymphoma, 14 WHO-EORTC classification marginal zone lymphoma, 136, 140 DAB389IL-2 see denileukin diftitox common leukocyte antigen, histiocytic sarcoma, mycosis fungoides, large cell transformation, 253 delayed-type hypersensitivity reactions, 38, 39 530 CXCR4 d’emblee mycosis fungoides, 313, 315 complementary determining regions (CDRs), cutaneous T cell lymphoma, 14 denaturing gradient gel electrophoresis (DGGE), immunoglobulin H, 23 mycosis fungoides, 140, 258 24 Complement receptor type 1 (CR1), 12 CXCR5, follicular helper T cell lymphoma, 317 dendritic cells complete rearrangements, 24 cyclin D1 see Bcl-1 functions, 509 composite lymphomas, 172 cyclin D1 IgH fusion probe, 13 hyperplasia, angioimmunoblastic T cell angioimmunoblastic T cell lymphoma, 487 cyclin D2, mantle cell lymphoma, 227 lymphoma, 488, 493 corticosteroids cyclin D3, mantle cell lymphoma, 227 markers, definitions, 11 angioimmunoblastic T cell lymphoma, 487 cyclophosphamide, lymphomatoid ontogeny, 509–510 topical, cutaneous T cell lymphoma, 15 granulomatosis, 502 dendritic cell sarcoma, 513 coup de sabre, 54–55 cyclosporine denileukin diftitox CPG-7909, cutaneous T cell lymphoma, 20 Epstein–Barr virus-associated B cell adverse effects, 18 CpG oligodeoxynucleotides, cutaneous T cell lymphoma–immune dysregulation line, bexarotene and, 17–18 lymphoma, 20 421–422 cutaneous T cell lymphoma, 18 cutaneous germinal center lymphoma see subcutaneous panniculitis-like T cell mechanism of action, 18 primary cutaneous follicle center lymphoma, 336 2’-deoxycoformycin, cutaneous T cell lymphoma cytarabine, mantle cell lymphoma, 225 lymphoma, 19 cutaneous lymphocyte antigen (CLA), 89 cytogenetics dermal perivascular lymphocytic infiltrates, adult T cell leukemia/lymphoma, 475, 478 anaplastic large cell lymphoma, 284, 302 52–53 blastoid mantle cell lymphoma, 226 B cell chronic lymphocytic leukemia, 451, 467 dermal sclerosis, pigmented purpuric definition, 9 blastic marginal zone lymphoma, 163, 194 dermatosis, 94 mycosis fungoides, 255, 256, 260 Burkitt’s lymphoma, 198 dermatomyositis, 43, 45–46, 46, 46, 54 myeloid leukemia, 508 cutaneous myeloid dendritic cell dyscrasia, dermatophytid, 39 precursor B cell lymphoblastic lymphoma, 513, 532 dermatophytosis, adult T cell leukemia/ 196, 207 diffuse large B cell lymphoma, 190–191 lymphoma, 476 cutaneous lymphoid dyscrasia (CLD), 89–133 diffuse large B cell lymphoma, leg type, 191, desmoplakin I, erythema multiforme, 44 genetic polymorphism, 90 193, 214 desmoplakin II, erythema multiforme, 44 molecular analysis, 28 double-hit lymphoma, 197 DF-T1 see CD43 antigen triggers, 89 γ δ T cell lymphoma, 408 diffuse intermediate lymphocytic lymphoma see cutaneous mantle cell lymphoma see mantle cell Hodgkin lymphoma, 437, 443, 443–444 mantle cell lymphoma lymphoma hydroa vacciniforme-like-Epstein–Barr virus- diffuse interstitial granulomatous drug reactions, cutaneous monocytic dyscrasia see cutaneous associated T cell lymphoproliferative 55 myeloid dendritic cell dyscrasia disease, 417 diffuse large B cell lymphoma, 187–217,188, 189 cutaneous myeloid dendritic cell dyscrasia, 507, intravascular lymphoma, 219 angioimmunoblastic T cell lymphoma and, 513–514, 527, 528, 529, 531, 532 lymphocyte-predominant Hodgkin 487 case study, 527, 527–529, 531, 531–532 lymphoma, 437 B to T cell ratio, 190 cytogenetics, 513, 532 lymphomatoid papulosis, 277–278, 279 classification scheme, 188 light microscopic findings, 513 mantle cell lymphoma, 227 cytogenetics, 190–191 phenotypic studies, 513 natural killer cell/T cell lymphomas, 382, 398 differential diagnosis, 192 cutaneous T cell lymphoid dyscrasia, 89–90 peripheral T cell lymphoma, NOS, 318, 331 histogenetics, 188 cutaneous T cell lymphoma (CTCL) precursor B cell lymphoblastic lymphoma, large cells, 189, 200, 203 adaptive immunity defects, 14 196, 210, 211, 212 leg type see diffuse large B cell lymphoma, leg cytotoxic chemotherapy, 19–20 primary cutaneous follicle center lymphoma, type diagnostic work-up, 14–15 172–173, 191 light microscopic findings, 189–190, 200, 201, innate immunity defects, 14 T cell prolymphocytic leukemia, 453, 203 PCR, 25, 26 453–454, 467 methotrexate-associated, 420 precursor lesions, 89–133 cytokines molecular studies, 202, 205

bindex 546 19 November 2015 7:21 PM 279mm×216mm Index 547

pathogenesis, 191–192 lymphomatoid papulosis with a rearrangement Hodgkin lymphoma, 435, 437, 438 phenotype, 190, 201, 204 of chromosome 6p25.3, 279, 303 hydroa vacciniforme-like lymphoma, 386 phenotypic profile, 187, 191 Dutcher bodies, marginal zone lymphoma, 136, intravascular lymphoma, 219 as post-transplant lymphoproliferative disease, 151, 189 latency-associated viral proteins, 382, 421, 488 419, 426 latent infection, 421–422 prognosis, 187 EBV see Epstein–Barr virus (EBV) latent membrane proteins, 421 recurrence, 188 eccrine coil lymphomatoid granulomatosis, 499, 501 small cells, 189 lymphomatoid papulosis, 277, 293 natural killer cell/T cell lymphoma, 382, 384, systemic, 197–198 mycosis fungoides, 240–241 396, 415 variants, 187, 192 subcutaneous panniculitis-like T cell of the elderly, 385 diffuse large B cell lymphoma, follicular center lymphoma, 336, 341 nuclear antigens, 421 cell origin see primary cutaneous follicle eczematoid purpura of Doucas and Kapetanakis, plasmablastic lymphoma, 419 center lymphoma (PCFCL) 93 post-transplant lymphoproliferative disease, diffuse large B cell lymphoma, leg type, 188, eczematous dermatitis, 37–40 417–418 192–193 drug-induced, 39 progressive B cell immortalization, 421–422 angiocentricity, 189, 200 subacute, 40–42 Epstein–Barr virus-associated hemophagocytic case studies, 200, 200–202 edematous and scarring vasculitic panniculitis, lymphohistiocytosis, 416 cytogenetics, 191, 193, 214 416 Epstein–Barr virus-associated latent small genetics, 193 enteropathy type T cell lymphoma, 406 nuclear RNA (EBER)-1, 13 light microscopic findings, 189, 193, 200, 201 celiac disease, 352, 407 Epstein–Barr virus-associated lymphomagenesis, pathogenesis, 191, 192 clinical features, 405, 406, 407 421 phenotypic profile, 187, 190, 193 EORTC see European Organization for the Epstein–Barr virus-associated proangiogenic micromilieu, 191 Research and Treatment of Cancer lymphoproliferative disease, 415–434 treatment, 193 (EORTC) case studies, 423–431, 423–431 diffuse lymphocytic infiltrates, autoimmune eosinophilia-myalgia syndrome, 55 in iatrogenic immune dysregulation setting, disease associated, 53–56 eosinophilic dermatosis of hematological 417–420 diffuse lymphoid dermal infiltrates without malignancy, 450 Epstein–Barr virus-associated mucocutaneous atypica, 51–53 eosinophilic ulcer of the tongue, 275 ulcer, 421, 438 2’,2’-difluoro-deoxycytidine see gemcitabine epidermotropic marginal zone lymphoma, Epstein–Barr virus+ cutaneous B cell digitate dermatosis, 41, 91 140–141 lymphoproliferative disorder of the dilutions, 13 epidermotropism elderly, 420–421, 428, 429 discoid lupus erythematosus cutaneous T cell lymphoma, 14 case study, 428, 428–429 differential diagnosis, 53 γ δ T cell lymphoma, 407, 413 differential diagnosis, 420–421, 435, 438 histopathology, 50 Langerhans cell histiocytosis, 511, 518 light microscopic findings, 420 nonscarring, 53–54, 56 mycosis fungoides, 247, 248, 249 lymphomatoid granulomatosis, 500 clinical features, 53, 53 primary cutaneous aggressive epidermotropic pathogenesis, 421 histopathology, 53–54 cytotoxic CD8+ T cell lymphoma, 353, phenotypic studies, 420 DJ130c see CD16 antigen 357 prognosis, 420 DK24 see CD7 antigen primary cutaneous CD4+ small/medium- Epstein–Barr virus-encoded RNA (EBER) double-hit lymphoma, 187, 197–198, 212, 213, sized pleomorphic T cell lymphoma, 316, aggressive NK cell lymphoma, 381 214 320, 324, 326, 327 assays, 13 cytogenetics, 197 small cell anaplastic large cell lymphoma, 282 diffuse large B cell lymphoma, 190 definition, 197 epitheliotropic T cell dyscrasia, 119, 130 Epstein–Barr virus+ B cell lymphoproliferative differential diagnosis, 198 epitheliotropism disease of the elderly, 429 extranodal involvement, 197 HIV-associated CD8 pseudolymphoma, 368 hydroa vacciniforme-like-Epstein–Barr virus- light microscopic findings, 197, 212 large plaque parapsoriasis, 90 associated lymphoproliferative disease, phenotypic profile, 198, 212, 213 lymphomatoid papulosis, 294 417, 431 doxorubicin, Epstein–Barr virus-associated mycosis fungoides, 247, 248, 259 natural killer-like CD4+ T cell lymphoma, 396 post-transplant lymphoproliferative primary cutaneous aggressive epidermotropic plasmablastic lymphoma, 424 disease, 422 cytotoxic CD8+ T cell lymphoma, 362 plasmacytic marginal zone lymphoma, 425 DRESS syndrome, 244 primary cutaneous follicle center lymphoma, post-transplant lymphoproliferative disease, drug-associated CD8+ pseudolymphoma, 356, 170 426 370, 370 small cell anaplastic large cell lymphoma, 286 Epstein–Barr virus-encoded RNA 1 (EBER-1), drug-associated granulomatous T cell dyscrasia, epithelium hyperplasia, syringolymphoid 13 32, 32 hyperplasia with alopecia, 97, 115, 116 Epstein–Barr virus-encoded RNA 2 (EBER-2), drug-associated pseudomycosis fungoides Epstein–Barr virus (EBV), 415, 421 13 (pseudo-MF) see lymphomatoid drug 30-bp deletion, 421 Epstein–Barr virus latent antigen 3C (EBNA3C), eruptions acute infection, 415 421 drug-associated reversible T cell dyscrasia, 258 anaplastic large cell lymphoma, 415 Epstein–Barr virus-positive T-cell dominant T cell clones, 61–62 angioimmunoblastic T cell lymphoma, lymphoproliferative disease (LPD) of molecular profile, 82, 82 486–487, 488, 489 childhood, 416 drug reactions antiapoptotic mechanisms, 421 Epstein–Barr virus receptor see CD21 antigen graft-versus-host disease vs., 45 blastic plasmacytoid dendritic cell neoplasm, Epstein–Barr virus-related large B cell idiopathic erythroderma, 96 510 lymphoma, 500, 505 DUSP22 CD30-positive large B cell lymphoma, 285, Epstein–Barr virus+ T cell lymphoproliferative anaplastic large cell lymphoma, 284, 303, 299, 299 disease of the elderly, 421 303–304 classification, 4 Erdheim–Chester disease, 511, 515

bindex 547 19 November 2015 7:21 PM 279mm×216mm 548 Index eruptive dermatofibroma, 156, 156–157 fluocinonide, mycosis fungoides, 15 differential diagnosis, 338–339, 408 erythema annulare centrifugum (EAC) fluorescent capillary electrophoresis, 25, 26 extracutaneous involvement, 404 deep variant, 42, 52–53 mycosis fungoides, 28 indolent expression, 405–406 drug-induced, 48, 53 fluorescent in-situ hybridization (FISH), 13 light microscopic findings, 407, 409, 410, 411, superficial, 42, 52–53 chronic lymphocytic leukemia, 451, 468 412, 413 erythema chronicum migrans, 42, 53 see also in situ hybridization studies molecular studies, 408 erythema gyratum repens, 42, 53 fluoxetine, mycosis fungoides exacerbation, 60 phenotypic studies, 407–408, 412 erythema marginatum, 42, 53 follicle center lymphoma see primary cutaneous prognosis, 406–407 erythema multiforme, 42–44 follicle center lymphoma (PCFCL) subcutaneous presentation, 404–406, 407, 411 clinical features, 42–43, 43 follicular dendritic cell markers, definitions, ganciclovir, post-transplant lymphoproliferative differential diagnosis, 43 11–12 disease, 422 drug-induced, 43 follicular dendritic cell sarcoma, 516 gastrointestinal involvement, mycosis fungoides, 254 histopathology, 43 follicular helper T cell(s) gemcitabine pathogenesis, 43–44 angioimmunoblastic T cell lymphoma, 488 cutaneous T cell lymphoma, 20 erythrodermic mycosis fungoides, 243–251 chronic lymphocytic leukemia, 452 Epstein–Barr virus-associated post-transplant differential diagnosis, 244 follicular helper T cell lymphoma, cutaneous, lymphoproliferative disease, 422 erythrophagocytosis 314–315 Gemzar see gemcitabine natural killer lymphomas, 397 clinical presentation, 314 generalized eruptive histiocytosis (GEH), 515, subcutaneous panniculitis-like T cell histologic findings, 316 525, 525, 526 lymphoma, 336 light microscopic findings, 314 germinal centers European BIOMED-2 collaborative study group, phenotypic studies, 314–315, 317 mantle cell lymphoma, 226 23, 26 follicular Hodgkin lymphoma, 436, 437 reactive see reactive germinal centers European Organization for the Research and follicular mucinosis, 241, 242, 245, 250 Gianotti–Crosti syndrome, 39, 44 Treatment of Cancer (EORTC) adult T cell leukemia/lymphoma, 475 histopathology, 44 combined ISCL classification see International drug-associated, 81, 81 giant follicular lymphoid hyperplasia see Society for Cutaneous Lymphoma (ISCL)/ drug reaction manifesting as, 98 Castleman disease EORTC idiopathic see alopecia mucinosa glomeruloid hemangiomas, 141 combined WHO classification see WHO- follicular mycosis fungoides, 98, 238, 239, 239, glucocorticoid-induced tumor necrosis factor EORTC classification 240–241 receptor family-related protein (GITR), diffuse large B cell lymphoma classification, case study, 29, 29, 30 adult T cell leukemia/lymphoma, 476 188 clinical presentation, 238, 239, 240 Gottron’s papule, 46 lymphoma classification, 2–7, 3 histologic features, 250, 253 Gougerot–Blum purpura, 93 extracorporeal photopheresis (ECP) light microscopic findings, 247 graft-versus-host disease (GVHD) cutaneous T cell lymphoma, 17 folliculolymphoid hyperplasia, 251 acute, 43, 44–45 mechanism of action, 17 folliculotropic lymphomatoid lupus clinical features, 44 Sézary syndrome, 17 erythematosus, 63 grading system, 44 side effects, 17 folliculotropic mycosis fungoides/pilotropic histopathology, 44–45 extramedullary plasmacytoma, 143 mycosis fungoides see follicular mycosis chronic (lichenoid), 50–51 fungoides clinical features, 50 factor XIIIA folliculotropic T cell lymphocytosis, 97–98, 240, histopathology, 50–51 dermal dendrocytes, 509 241 immunophenotyping, 51 generalized eruptive histiocytosis, 526 differential diagnosis, 98 pathogenesis, 45, 51 histiocytopathy of factor XIIIA perivascular light microscopy findings, 97–98 granulocytic sarcoma, 197, 197, 198, 199, 208, dermal dendritic cell origin, 509, 514–516 phenotypic studies, 98 208, 209 Rosai–Dorfman disease, 514 formalin-fixed paraffin-embedded (FFPE) granuloma annulare, chronic lymphocytic fascin, lymphomatoid papulosis, 277 skin biopsy, TCR-β gene rearrangement leukemia, 449 Fas ligand (FasL) analysis, 26 granulomatous eccrinotropic lymphomatoid acute graft-versus-host disease, 45 Fox P3 papulosis, 276, 293 mycosis fungoides, 257 adult T cell leukemia/lymphoma, 475, 481, granulomatous mycosis fungoides, 242, 242, 243, subcutaneous panniculitis-like T cell 483 268, 269 lymphoma, 337 definition, 9 case study, 31, 31, 35, 268, 268–270 fat lobule paraffin-embedded tissue panels, 12 in morphea lesions, 55 atypical lymphocytic lobular panniculitis, 101, framework regions, immunoglobulin H receptor, granulomatous slack skin, 242 107–108, 118, 345 437 granulomatous T cell dyscrasia, 60 lupus erythematosus profundus, 64 granulomatous T cell lymphoma, CD8+, 353 primary cutaneous follicle center lymphoma, γ δ T cell(s), 404 granzyme B 174 CD8-positive, 352 aggressive natural killer cell lymphoma, 392 fat necrosis, subcutaneous panniculitis-like T lichen planus, 47 anaplastic large cell lymphoma, 283, 291 cell lymphoma, 336, 340, 343 subcutaneous panniculitis-like T cell hydroa vacciniforme-like-Epstein–Barr virus febrile ulceronecrotic pityriasis lichenoides et lymphoma, 335–336 lymphoproliferative disease, 417 varioliformis acuta, 95 subsets, 404 mycosis fungoides, 255 fingertip hypertrophy, chronic lymphocytic γ δ T cell lymphoma, 404–414, 406 nasal natural killer cell/T cell lymphoma, 389, 390 leukemia, 449 autoimmune stigmata, 406 natural killer cell/T cell lymphomas, 381, 390 fish oil, polymorphous light eruption, 52 case studies, 409–410, 409–410 plasmacytoid dendritic cells, 510 flow cytometry, primary cutaneous follicle clinical features, 404–407, 406 primary cutaneous aggressive epidermotropic center lymphoma, 172 cytogenetic studies, 408 cytotoxic CD8+ T cell lymphoma, 354, fludarabine, cutaneous T cell lymphoma, 19 cytologic atypia, 407, 412, 413 359, 361

bindex 548 19 November 2015 7:21 PM 279mm×216mm Index 549

subcutaneous panniculitis-like T cell lymphocyte-predominant see lymphocyte- Kimura’s disease, 68 lymphoma, 344 predominant Hodgkin lymphoma mantle cell lymphoma, 225 type E lymphomatoid papulosis, 307 molecular studies, 437, 443–444 ICAM-1 see intercellular adhesion molecule 1 Grover’s-like disease, 45 phenotypic studies, 437, 441, 446, 447 (ICAM-1) gyrate erythemas, 53 primary cutaneous, 435, 445 ichthyosiform scale, atopic dermatitis, 41 putative T cell lineage, 437 ICOS, follicular helper T cell lymphoma, 317 Hand–Schuller–Christian disease, 510 secondary cutaneous, 435 idiopathic erythroderma, 96 Hashimoto–Pritzker disease, 511 subtypes, 436–438 light microscopic findings, 96 HD37 see CD19 antigen transcription factors deregulation, 438 molecular studies, 96, 124 HECA-452 see cutaneous lymphocyte antigen Hodgkin specific paraffin-embedded tissue Sézary syndrome vs., 96 (CLA) panels, 12 idiopathic follicular mucinosis see alopecia hemophagocytic syndrome, subcutaneous HTLV-1 see human T cell lymphotropic virus mucinosa panniculitis-like T cell lymphoma, 335 type 1 (HTLV-1) idiopathic pigmented purpuric dermatosis, 61 hemophagocytosis, γ δ T cell lymphoma, 407 human herpesvirus 6 (HHV-6) idiopathic polyclonal lymphadenopathy with hepatitis C virus angioimmunoblastic T cell lymphoma, 489 polyclonal hypergammaglobulinemia, 142 lichen planus-like eruptions, 48 pityriasis rosea, 39 id reaction (autoeczematization), 39–40, 65 marginal zone lymphoma, 138 human herpesvirus 7 (HHV-7), pityriasis rosea, IgH see immunoglobulin heavy chain (IgH) subcutaneous panniculitis-like T cell 39 IGH@BCL-2/t(14;18)(q32;q21) rearrangement, lymphoma, 337, 343, 343–344, 344 human herpesvirus 8 (HHV-8) double-hit lymphoma, 197 hepatobiliary disease, lichen planus-like angioimmunoblastic T cell lymphoma, 489 imiquimod eruptions, 48 assay, 13 cutaneous T cell lymphoma, 16, 20 hepatosplenic T cell lymphoma, clinical features, Castleman disease, 141, 142 topical, mycosis fungoides, 16 405, 407 plasmablastic lymphoma, 419 immune dysregulation herald patch, pityriasis rosea, 39 treatment, 419 drug-induced, marginal zone lymphoma, 138 herpes gestationis, 41–42 human immunodeficiency virus (HIV) iatrogenic herpes labialis, primary cutaneous Castleman disease, 142 Epstein–Barr virus-associated plasmacytoma, 144 CD8 pseudolymphoma, 356, 368, 368, 369 lymphoproliferative disease, 417–420 herpes virus-associated lymphomatoid Hodgkin lymphoma, 435 post-transplant lymphoproliferative disease, dermatitis, 65 interface dermatitis, 45 417–420 herpes virus infection, erythema multiforme, seborrheic dermatitis, 41 intravascular lymphoma, 218 43–44 human T cell lymphotropic virus type 1 (HTLV- lymphomatoid drug eruptions, 59–60 HHV8 see human herpesvirus 8 (HHV-8) 1) lymphomatoid granulomatosis, 500 histiocytes adult T cell leukemia/lymphoma, 473, 475, immunoblasts benign intravascular proliferations, 220 481 angioimmunoblastic T cell lymphoma, 487, granulomatous mycosis fungoides, 268 infective dermatitis of childhood, 473 492, 495 lupus erythematosus profundus, 64 mycosis fungoides, 257, 476 diffuse large B cell lymphoma, leg type, 193, primary cutaneous CD4+ small/medium- transmission modes, 473 200 sized pleomorphic T cell lymphoma, 320 Hu-MaxCD4 (zanolimumab), 18 immunocytoma, 139, 143, 419, 425 histiocytic cytophagic panniculitis see hydroa vacciniforme, 52 case study, 425, 425 subcutaneous panniculitis-like T cell hydroa vacciniforme-like-Epstein–Barr virus- clinical features, 134–135, 135 lymphoma associated T cell lymphoproliferative differential diagnosis, 139 histiocytic sarcoma, 513, 515–516, 530, 530 disease, 415, 416–417, 430–431 EBER-positive, 137 histiocytopathy of factor XIIIA perivascular clinical features, 416 pathogenesis, 138 dermal dendritic cell origin, 509, cytogenetic studies, 417 pathology, 136 514–516 differential diagnosis, 417 sclerosing (scleromyxedema-like), 136, 136 histiocytopathy of myeloid dendritic cell origin, light microscopic findings, 416–471, 430 immunoglobulin(s) 513–514 lymphoma, progression to, 416, 417 precursor B cell lymphoblastic lymphoma, 196 histiocytosis X see Langerhans cell histiocytosis hydroa vacciniforme-like eruptions, 416 synthesis dysregulation, Hodgkin lymphoma, histone deacetylase inhibitors (HDACi), hydroa vacciniforme-like lymphoma (HVLL), 438 cutaneous T cell lymphoma, 19 385–386, 416 immunoglobulin D (IgD), primary B cell HIV see human immunodeficiency virus (HIV) light microscopic findings, 386 lymphoma of leg type, 172 HLA-DR, definition, 12 phenotypic studies, 386 immunoglobulin G (IgG) Hodgkin lymphoma, 435–448, 436, 436 hydrocortisone, mycosis fungoides, 15 herpes gestationis, 42 case studies, 439–446, 439–446 hypercalcemia, adult T cell leukemia/lymphoma, primary cutaneous follicle center lymphoma, classic, 436, 439, 440, 441 476 173, 191 clinical features, 435 hypopigmented epitheliotropic T cell dyscrasia, immunoglobulin gene rearrangement analysis, cytogenetics, 437, 443, 444 91, 91–92 23 differential diagnosis, 420, 435, 437, 438 hypopigmented interface T cell dyscrasia, 91, 91, angioimmunoblastic T cell lymphoma, Epstein–Barr virus infection, 435, 437, 438 91–92, 240 488–489 extracutaneous dissemination, 435 light microscopic findings, 92 immunoglobulin heavy chain (IgH) fibrosing reaction, 445 molecular studies, 92, 123 consensus sequence, 23 follicular, 436, 437 phenotypic studies, 92 family-specific sequence, 23 histogenesis, 437–438, 444 hypopigmented mycosis fungoides, 240 rearrangements, 23 HIV and, 435 lymphocytoma cutis, 66 indolent clinical course, 435 ibrutinib marginal zone lymphoma, 137 light microscopic findings, 436, 439, 440, 441 angiolymphoid hyperplasia with eosinophilia, 68 structure, 23–24 lymphocyte-depleted variants, 436 chronic lymphocytic leukemia, 452 variable heavy (VH segments), 23

bindex 549 19 November 2015 7:21 PM 279mm×216mm 550 Index immunoglobulin light chains, 10 interferon-α 2b (IFN-α 2b), lymphomatoid JAK3, T cell prolymphocytic leukemia, 453, 454 immunoglobulin M (IgM), diffuse large B cell granulomatosis, 502 Jessner’s lymphocytic infiltrate of the skin, 53, lymphoma, leg type, 172, 193 interferon-γ (IFN-γ) 56, 65 immunosuppression CD8+ lymphomatoid papulosis, 278 clinical features, 56 Epstein–Barr virus-associated mucocutaneous laboratory abnormalities, 17 JUNB, Sézary syndrome, 257 ulcer, 421 interleukin-3 receptor (IL3R), blastic juvenile springtime eruption, 52 post-transplant lymphoproliferative disease, plasmacytoid dendritic cell neoplasm, 383 juvenile temporal arteritis, 68 418 interleukin-6 (IL-6) juvenile xanthogranuloma, 509, 524, 524 immunotoxins, cutaneous T cell lymphoma, 18 Castleman disease, 141, 142 light microscopic findings, 514, 524 incipient pilotropic T cell dyscrasia, 98, 117, primary cutaneous plasmacytoma, 144 117 interleukin-8 (IL-8), pyogenic anaplastic large kappa light chain restriction incomplete rearrangements, 24 cell lymphoma, 282 blastic marginal zone lymphoma, 162 indeterminate cell proliferative disorder, interleukin-10 (IL-10) lymphocytoma cutis, 66 511–512, 520, 520, 521 mycosis fungoides, 258 marginal zone lymphoma, 136, 137–138, 139, indigenous dermal dendrocyte, 509 nickel allergy, 37 149, 153, 155 indolent CD8 lymphoid proliferation of the ear, interleukin-12 (IL-12), cutaneous T cell karyorrhexis, subcutaneous panniculitis-like T 374, 374 lymphoma therapy, 20 cell lymphoma, 336 indolent CD8 positive lymphoid proliferation of interleukin-15 (IL-15), mycosis fungoides, 258 4 KB128, 10 the face, 312, 355 interleukin-17 (IL-17), adult T cell leukemia/ keratoderma, 99 case study, 372–374, 372–374 lymphoma, 476 keratoderma-like T cell dyscrasia, 99–100, 130 clonality studies, 355 interleukin-32 (IL-32), mycosis fungoides, 258 drug-induced, 100 differential diagnosis, 355 International Society for Cutaneous Lymphoma light microscopic findings, 99, 130 histomorphology, 353 (ISCL)/EORTC pathogenesis, 100 light microscopic findings, 355, 372, 375 body surface area involved calculation, 4 phenotypic studies, 99–100, 131 phenotypic studies, 355, 373, 374 mycosis fungoides TNM classification, 4, 4–5, Ki-1, 274 treatment, 355 245–246, 246 see also CD30 antigen infectious mononucleosis, 415 non-mycosis fungoides/Sézary syndrome Ki-67 infective dermatitis of childhood, 473, 476 TNM classification, 5, 5 definition, 12 in situ hybridization studies Sézary syndrome TNM classification, 4, 4–5, diffuse large B cell lymphoma, leg type, 201 adult T cell leukemia/lymphoma, 475, 481 245–246, 246 nasal type natural killer cell/T cell lymphoma, diffuse large B cell lymphoma, 190, 202, 205 interstitial granulomatous drug reaction, 60, 60, 398 diffuse large B cell lymphoma, leg type, 202 242, 243 subcutaneous panniculitis-like T cell lymphocytoma cutis, 66 interstitial mycosis fungoides, 242–243 lymphoma, 337 lymphomatoid granulomatosis, 500, 505 intestinal lymphomatosis, mantle cell kidneys, mycosis fungoides, 254 marginal zone lymphoma, 149, 153, 155 lymphoma, 225 Kiel classification, 1–2, 2 plasmablastic lymphoma, 427 intravascular anaplastic large cell lymphoma, killer cell inhibitory receptor (KIR) primary cutaneous follicle center 219–220, 282–283 natural killer cell/T cell lymphomas, 381 lymphoma, 205 intravascular large cell lymphoma see natural killer-like CD4+ T cell lymphoma, 385 primary cutaneous plasmacytosis, 67 intravascular lymphoma primary cutaneous aggressive epidermotropic integrin-associated protein, intravascular intravascular lymphoma, 218, 218–224 cytotoxic CD8+ T cell lymphoma, 354 lymphoma, 219 B cell, 218 killer receptor p140/KIR3DL2 (KIR) (CD158K) intercellular adhesion molecule 1 (ICAM-1) case study, 221, 221–222 mycosis fungoides, 244 diffuse large B cell lymphoma, 192 clinical features, 218–219 Sézary syndrome, 244 intravascular lymphoma, 219, 222 cutaneous variant, 218 Kimura’s disease, 67–68 mycosis fungoides, 257 cytogenetic studies, 219 KP1 see CD68 antigen interdigitating dendritic cell sarcoma, 516 differential diagnosis, 219 interface dermatitis immune dysregulation states, 218 L26 see CD20 antigen cell-poor vacuolar, 42–46 light microscopic findings, 219 labial herpes, primary cutaneous plasmacytoma, differential diagnosis, 42 molecular studies, 219 144 HIV infection, 45 pathogenesis, 219 lactate dehydrogenase (LDH), 5 lichenoid pattern, 46–51 phenotypic profile, 219, 222 lacunar cells, Hodgkin lymphoma, 437, 441 lymphomatoid drug reaction, 69 T cell phenotype, 219 LAM-1 see CD62L selectins nonscarring discoid lupus erythematosus, 54 treatment, 219 lambda light chain restriction interferon(s), cutaneous T cell lymphoma intravascular natural killer T cell lymphoma, immunocytoma, 139 therapy, 17 219, 386 lymphocytoma cutis, 66 interferon dendritic cell (IF-DC), 509–510, 513 inv(2)(p23q35), 284 marginal zone lymphoma, 136, 137, 138, 139, interferon regulatory factor (IFR), Hodgkin investigational therapies, cutaneous T cell 149, 153, 155 lymphoma, 438 lymphoma, 20 Langerhans cell histiocytosis, 510–511 interferon regulatory factor-4 (IRF4) see IP-10, lymphomatoid granulomatosis, 501 adults, 510 MUM-1 IRF-4 protein see MUM-1 case study, 518, 518, 519 interferon regulatory factor-4 (IRF4)-breakapart iso8q, T cell prolymphocytic leukemia, 453 classic, 511, 518, 519 dual color probes, 13 isotretinoin Langerhans sarcoma vs., 512 interferon regulatory factor 5 (IFR), Hodgkin cutaneous T cell lymphoma, 17 light microscopic features, 511, 518, 519 lymphoma, 438 side effects, 17 pathogenesis, 510–511 interferon-α (IFN-α) phenotypic studies, 511 cutaneous T cell lymphoma therapy, 17 JAK1, T cell prolymphocytic leukemia, 453, 454 Langerhans cells, 509, 510 laboratory abnormalities, 17 JAK2, chronic myeloproliferative disease, 508 Langerhans cell histiocytosis, 510, 511

bindex 550 19 November 2015 7:21 PM 279mm×216mm Index 551

Langerhans sarcoma, 512–513, 522, 523 pathogenesis, 47, 47 molecular studies, 66, 79 case study, 522, 522–523 lichen planus-like eruptions pathogenetic basis, 65 differential diagnosis, 512–513 hepatobiliary disease, 48 phenotypic studies, 65–66 immunohistochemistry, 512 secondary syphilis, 48 T cell clonality, 59, 79 Langerhans cell histiocytosis vs., 512 lichen sclerosis/morphea overlap, 55 triggers, 65 prognosis, 512 lichen sclerosus, lymphomatoid, 64–65 lymphoma classifications, 1–8 langerin light chain restriction see also individual classification schemes definition, 11 Castleman disease, 142, 165 lymphomatoid drug eruptions, 59–61 Langerhans cell histiocytosis, 510, 511, 518 primary cutaneous follicle center lymphoma, case studies, 69–77, 69–77, 80–82, 80–82 Langerhans sarcoma, 512, 523 172 clinical features, 59–60, 60 large B cell lymphoma, CD30-positive see CD30- primary cutaneous plasmacytosis, 67 clinical history, 61 positive large B cell lymphoma lipoprotein lipase (LPL), chronic lymphocytic differential diagnosis, 61, 62 large cell lymphoma, 170 leukemia, 451 histopathology, 60–61 large granular cell leukemia, 384, 416 LMP, Hodgkin lymphoma, 438 immune dysregulation, 59–60 differential diagnosis, 454 Lukes–Collins classification, lymphoma, 1–2 molecular profile, 61–62, 80–81, 80–81 large plaque parapsoriasis (LPP), 90, 90–91 lung involvement pathogenetic basis, 62 clinical features, 90 mycosis fungoides, 254 patterns, 59 differential diagnosis, 91 subcutaneous panniculitis-like T cell phenotypic studies, 61 hypopigmented, 91, 123 lymphoma, 335 lymphomatoid granulomatosis (LYG), 499–506 light microscopy findings, 90 lupus band test, lupus erythematosus profundus, case studies, 503–505, 503–505 molecular profile, 90, 124, 125 64 in children, 499 latent membrane protein 1, 421 lupus erythematosus clinical features, 499–500, 500, 500 latent membrane proteins, Epstein–Barr virus, concomitant subcutaneous panniculitis-like T clonality studies, 501 421 cell lymphoma, 338 differential diagnosis, 420, 500, 501–502 LECAM-1 see CD62L selectins polymorphous light eruption vs., 52 Epstein–Barr virus, 499, 501 Leder, 209, 509 lupus erythematosus profundus (LEP), 63–64, grades, 500 lenalidomide, diffuse large B cell lymphoma, leg 101 histogenesis, 501 type, 193 case studies, 84, 84 histopathology, 500–501, 503, 504, 505 Lennert’s lymphoma, 318, 337 clinical features, 63 immune dysregulation, 500 lethal midline granuloma and sinonasal differential diagnosis, 64, 334, 336–337, 408 immunophenotyping, 500 lymphoma see nasal natural killer cell/T histomorphology, 64 post-transplant, 500 cell lymphoma immunofluorescent studies, 64 treatment, 502 Letterer–Siwe disease, 510, 511 light microscopic findings, 338 vascular pathology, 500–501, 503, 504 Leu1 see CD5 antigen lymphomatoid vasculitis, 63 lymphomatoid hypersensitivity reaction, 39 Leu2a see CD8 antigen molecular profile, 84, 84 CD30-positive lymphoproliferative disorders, Leu3a see CD4 antigen phenotype, 337, 348 274 Leu4 see CD3 antigen subcutaneous panniculitis-like T cell lymphomatoid drug reaction, 69 Leu5 see CD2 antigen lymphoma vs., 64, 334, 336–337, 338, 342 lymphomatoid lichen sclerosus, 64–65 Leu6 see CD1a antigen lupus profundus see lupus erythematosus lymphomatoid lupus erythematosus, 63 Leu7 see CD7 antigen profundus (LEP) lymphomatoid papulosis, 274–278, 276 Leu16 see CD20 antigen Lyme disease, 46, 53 anaplastic large cell lymphoma vs., 280, 281 leukemia cutis, 507–509 lymphoblastic leukemia, 195 CD8 variant, 276, 278, 354, 354–355, 366, 367 chronic lymphocytic leukemia, 449 lymphoblastic lymphoma, 195 case studies, 292, 293–294, 293–295, 366, light microscopic findings, 509 lymphoblasts, precursor B cell lymphoblastic 366–367 phenotypic studies, 509 lymphoma, 196 cytokine milieu, 354 lichen aureus, 93, 93 lymphocyte(s) differential diagnosis, 278, 354 lichenoid and granulomatous dermatitis, 48 B see B cell(s) histogenesis, 278 lichenoid connective tissue disease syndromes, large plaque parapsoriasis, 90 light microscopic findings, 278, 292, 48–50 mantle cell, 226 354–355, 366, 367 clinical features, 49 primary cutaneous follicle center lymphoma, pathology, 277, 292, 295 histopathology, 49–50 169 vasculitic changes, 354, 366 immunofluorescent findings, 50 T see T cell(s) in children, 275 pathogenesis, 50 lymphocyte function antigens (LFAs) clinical features, 274–276, 275 lichenoid drug reactions, 48 allergic contact dermatitis, 39 cytogenetics, 277–278 causes, 48 diffuse large B cell lymphoma, 192 diagnostic criteria, 274 clinical features, 48, 48 lymphocyte-predominant Hodgkin lymphoma, differential diagnosis, 277, 278, 501 lichenoid interface dermatitis, 46–51 436–437 intraoral involvement, 275 lichenoid mycosis fungoides, 246, 251, 252 categories, 436–437 lymphoma, progression to, 274–275 lichen planus vs., 247 cytogenetics, 437 molecular studies, 277, 300, 300–301, 301 lichenoid photodermatitis, 40, 40 germinal cell transformation, 437 persistent agminated, 275 lichen planus, 46–48 nodular (follicular Hodgkin lymphoma), 436, phenotypic studies, 277, 291, 292 basal layer squamotization, 48 437 prognosis, 276 cellular cytotoxicity, 47, 47 lymphocytic and granulomatous eccrinotropic with a rearrangement of chromosome 6p25.3, clinical features, 46, 47 lymphomatoid papulosis, 354, 366, 367 276, 279–280 histopathology, 47–48 lymphocytoma cutis, 56, 59, 60, 61, 65–66 regional, 275 immunophenotyping, 51 case studies, 70–71, 70–71, 74, 74, 77, 77–79 treatment, 279 lichenoid mycosis fungoides vs., 247 light microscopic findings, 65 type A, 62, 274, 276

bindex 551 19 November 2015 7:21 PM 279mm×216mm 552 Index lymphomatoid papulosis (continued) differential diagnosis, 139 cutaneous T cell lymphoma, 18–19 drug-induced immune dysregulation, 138 Sézary syndrome, 19 angiocentric infiltrates, 276 epidermotropic, 140–141 molecular analysis/profiles, 23–36 case studies, 292, 292 molecular studies, 27, 137–138, 158 alopecia mucinosa, 99, 114, 116, 126 molecular studies, 300–301 oncogenes, 138–139 anaplastic large cell lymphoma, 301 pathology, 276–277, 290, 292, 293, 294, 296 pathogenesis, 138 angioimmunoblastic T cell lymphoma, phenotypic studies, 277 pathology, 135–136, 145, 146, 147, 148, 149, 488–489 type B, 274, 276, 276–277, 278 150, 151, 152, 153, 154, 155 atypical lymphocytic lobular panniculitis, 101, type C, 274, 276, 276, 277, 279, 290 phenotype, 136–137 127, 129 case studies, 290, 290–291, 296, 296 prognosis, 134, 135 B cell chronic lymphocytic leukemia, 451 type D, 274, 276, 276, 278, 306, 354 relapse rate, 134, 135 blastic plasmacytoid dendritic cell neoplasm, type E, 274, 276, 276, 278–279, 307, 307, 308, 354 sclerosing variant, 157 383 case study, 307, 307 systemic, 134 case studies, 29–35 variants/types, 274, 275–276, 276 T-cell rich variants, 136–137 CD30-negative large cell T cell lymphoma, 318 lymphomatoid tissue, reactive see reactive treatment, 135 cutaneous lymphoid dyscrasia, 28 lymphomatoid tissue mast cells diffuse large B cell lymphoma, 190, 202, 205 lymphomatoid vascular reaction, 500, 500 chronic graft-versus-host disease, 51 drug-associated reversible T cell dyscrasia, lupus erythematosus profundus, 63 hyperplasia, angioimmunoblastic T cell 61, 82, 82 lymphomatoid drug eruptions, 60 lymphoma, 489 epitheliotropic T cell dyscrasia, 119 lymphomatous adult T cell leukemia/lymphoma, mast/stem cell growth factor receptor (SCFR), γ δ T cell lymphoma, 408 473, 474, 482, 482, 483 11 HIV-related CD8 pseudolymphoma, 356 lymphopoietin, mycosis fungoides, 258 mature plasmacytoid dendritic cell Hodgkin lymphoma, 443–444 lymphoproliferative disease, paraffin-embedded proliferations, 513–514 hydroa vacciniforme-like-Epstein–Barr virus- tissue panels, 12 Max–Joseph spaces, 48 associated T cell lymphoproliferative lymphoproliferative disease of granular mdm2 protein, NK/T cell lymphomas, 382 disease, 417 lymphocytes (LDGLs), 384 mechlorethamine, 15 hypopigmented interface T cell dyscrasia, 92, lysozyme, 11 mycosis fungoides, 15 123 MEDI-507, cutaneous T cell lymphoma therapy, idiopathic erythroderma, 96, 124 MadCAM-1, marginal zone lymphoma, 137 18 intravascular lymphoma, 219 Majocchi’s purpura annularis telangiectoides, 93 MEL-14 see CD62L selectins large plaque parapsoriasis, 90, 124, 125 major histocompatibility class (MHC) II memory T cells lupus erythematosus profundus, 84, 84 antigens, dendritic cells, 509 cutaneous lymphoid dyscrasia, 89 lymphocyte-predominant Hodgkin malignant angioendotheliomatosis see Sézary syndrome, 245 lymphoma, 437 intravascular lymphoma metastatic extramedullary plasmacytoma, lymphocytoma cutis, 66, 79 malignant melanoma, 515 142–143 lymphomatoid drug eruptions, 61–62 MALT1 breakapart probe, 13 methotrexate lymphomatoid drug reaction, 80–81, 80–81 MALT1 gene CD30-positive large B cell lymphoma lymphomatoid papulosis, 300–301 marginal zone lymphoma, 137, 138, 139 development, 285, 299, 299 mantle cell lymphoma, 225, 227 primary cutaneous follicle center lymphoma, 173 Epstein–Barr virus-associated B cell marginal zone lymphoma, 27, 158 MALT1 IgH fusion probe, 13 lymphoma–immune dysregulation line, microdissection, 27 mantle cell lymphoma, 225, 225–235 421–422 mycosis fungoides, 26–27, 256–257, 261–265 blastoid/blastic see blastoid mantle cell lymphomatoid papulosis, 279 natural killer cell/T cell lymphomas, 382, 385 lymphoma lymphoproliferative disease associations, 420 peripheral T cell lymphoma, not otherwise case studies, 229–232, 229–232 8-methoxypsoralen (8-MOP), 17 specified, 318 clinical features, 225 MI15, 10 pigmented purpuric dermatosis, 27, 35, 94, cytogenetic profile, 227, 233 MIB-1 see Ki-67 107–108, 122–123, 128 diffuse pattern, 226 microdissection, molecular analysis, 27 pityriasis lichenoides, 95–96, 120–121 Ig gene rearrangement, 138 microRNAs pityriasis lichenoides chronica, 27, 33, 34, 119 large nodular pattern, 226 chronic lymphocytic leukemia, 451 primary cutaneous B cell lymphoma, 27 light microscopic findings, 225–226, 229, 231 primary cutaneous follicle center lymphoma, primary cutaneous CD4+ small/medium- lymph node involvement patterns, 225–226 173 sized pleomorphic T cell lymphoma, 318 mantle zone pattern, 226 microvesicles, pityriasis lichenoides chronica, primary cutaneous follicle center lymphoma, molecular studies, 225, 227 104 27, 172 pathogenesis, 227–228 MIG subcutaneous panniculitis-like T cell phenotypic profile, 226–227, 230, 232 lymphomatoid granulomatosis, 501 lymphoma, 337 prognosis, 225 marginal zone lymphoma, 140 syringolymphoid hyperplasia with alopecia, 97 small nodular pattern, 226 mixed connective tissue disease (MCTD) T cell prolymphocytic leukemia, 468 therapy, 225 clinical features, 49 utility, 26–27 VH gene mutation, 227 diagnostic criteria, 50 value, 26–27 marginal zone, 138 histopathology, 50 molluscum contagiosum, viral-associated marginal zone lymphoma, 134–139, 135, 135 immunofluorescent findings, 50 lymphomatoid dermatitis, 65 B cell dominant forms, 136–137 mixed lymphoma, 170 monoclonal antibodies, cutaneous T cell blastic transformation, 136, 137, 140 MLL gene, precursor B cell lymphoblastic lymphoma therapy, 18–19 case studies, 145–155, 145–155, 158, 158 lymphoma, 196, 210 monoclonal B cell lymphocytosis, 449, 450 clinical features, 134–135 MOC1 see CD56 markers monocyte, 533 cytogenetic abnormalities, 138–139 mogamulizumab monocytoid cells cytomorphology, 147 adult T cell leukemia/lymphoma, 475 mantle cell lymphoma, 226, 229, 231

bindex 552 19 November 2015 7:21 PM 279mm×216mm Index 553

marginal zone lymphoma, 136 definition, 236 myeloperoxidase, 11 monomorphic post-transplant demographics, 236 myxoid anaplastic large cell lymphoma, 283, 305, lymphoproliferative disease, 418 differential diagnosis, 258, 474 305, 306 morbiliform drug eruption, 45 drug reaction vs., 258 myxovirus resistance protein A (MXA) morbiliform viral exanthem, 45 early, 246, 246 blastic plasmacytoid dendritic cell neoplasm, morphea, 54–56 epigenetic factors, 258 383 clinical features, 54, 54–55 extracutaneous involvement, 239, 254 cutaneous myeloid dendritic cell dyscrasia, 529 differential diagnosis, 55 follicular mucinosis, 245, 253 definition, 11 generalized, 54 folliculotropism, 245 dermatomyositis, 54 guttate form, 54 genomic microarray analysis, 257 γ δ T cell lymphoma, 407–408 histopathology, 55 historical perspective, 236 lupus erythematosus, 54 pathogenesis, 55–56 hypopigmented, 240 lupus erythematosus profundus, 63, 64, 337, subcutaneous (morphea profunda), 54 interstitial, 242–243 338, 348, 407–408 morphea profunda (subcutaneous morphea), 54 intraepidermal architecture, 246, 248, 249 subcutaneous panniculitis-like T cell mosquito bite hypersensitivity, 386, 416–417 lacunar spaces, 246, 248 lymphoma, 337, 348 pathogenesis, 416 large cell transformation, 245, 248, 251–254, MPL proto-oncogene, chronic myeloproliferative 259 narrowband UVA disease, 508 cell types, 254 cutaneous T cell lymphoma, 16 MT310 see CD4 antigen classification, 254 mycosis fungoides, 16 MT910 see CD2 antigen prognosis, 253 nasal natural killer cell/T cell lymphoma, 377, mucin lichenoid variant, 243 378, 379–380, 387, 388, 389, 390 atypical lymphocytic lobular panniculitis, 101 light microscopic findings, 61, 246–251 case studies, 378, 387–390, 387–390 γ δ T cell lymphoma, 407, 411 lymphomatoid lichen sclerosus vs., 64–65 clinical presentation, 378, 380 lupus erythematosus profundus, 64 molecular analysis, 26–27, 256–257, 261–265 pathology, 380–381, 387, 388 mucosal associated lymphoma (MALT)-like morphology, 246–251 nasal type natural killer cell/T cell lymphoma, lymphoma of the skin (MALTOMAS) see mortality rates, 236 377, 380, 380 marginal zone lymphoma partially treated, 251 case studies, 397, 397, 398 multiple myeloma, primary cutaneous patch stage, 236–237, 246, 247–248, 249 clinical presentation, 380 plasmacytoma and, 142–143 pathogenesis, 257–258 pathology, 380–381, 397, 398 multiple myeloma oncogene-1 see MUM-1 phenotypic profile, 254–256, 255, 256, 270 natural killer (NK) cell(s) multiple sclerosis, 63 plaque stage, 237, 246, 247, 248 biology, 377–379 multiplex ligation-dependent probe morphology, 248 function, 377 amplification (MLPA), diffuse large B cell primary cutaneous CD4+ small/medium- markers, 10, 378–379 lymphoma, leg type, 191 sized pleomorphic T cell lymphoma vs., mosquito bite hypersensitivity, 416 multiplex polymerase chain reaction, 24 316 paraffin-embedded tissue panels, 12 MUM-1 skin-directed therapies, 15–16 natural killer cell lymphoma blastic marginal zone lymphoma, 162 solitary, non-Woringer–Kolopp subtype, 241 blastoid form see blastic plasmacytoid diffuse large B cell lymphoma, leg type, 190, staging, 250 dendritic cell neoplasm 192 T cell clonality, 257 differential diagnosis, 338, 501–502 primary cutaneous follicle center lymphoma, therapy by stage, 14, 14 NK-like cell lymphoma vs., 377 171 treatment, 19 pathology, 381, 389 MXA see myxovirus resistance protein A (MXA) tumor stage, 237–239, 238, 239, 245 see also natural killer cell/T cell lymphomas MYC case studies, 259, 259–260 natural killer cell/T cell lymphomas, 377–403 diffuse large B cell lymphoma, leg type, 193 light microscopic findings, 248, 253, 259 case studies, 387–400, 387–400 double-hit lymphoma, 197 phenotypic profile, 255, 259, 260 categorization, 352, 377, 378 primary cutaneous follicle center lymphoma, prognosis, 245 CD56-negative, 382 173 variants, 239, 239 clinical course, 380 T cell prolymphocytic leukemia, 454 rare, 249 clinical presentation, 379 MYC amplification, 13 vesicular, 239, 241–242, 266, 266, 267 cytogenetics, 382, 398 MYC breakapart probe, 13 wiry sclerosis of collagen, 248, 249 differential diagnosis, 382 MYC IgH fusion probe, 13 MYC translocation, 13 Epstein–Barr virus, 382, 384, 396, 415 mycosis fungoides, 249 MYD88 L265P oncogenic mutation, diffuse large intravascular, 219, 386 acrosyringia/suprapapillary plates, 246, 248, B cell lymphoma, leg type, 191 molecular studies, 382 249, 250 myeloblast, 534 nasal see nasal natural killer cell/T cell angioimmunoblastic T cell lymphoma vs., 487 myelodysplastic syndrome (MDS), 508 lymphoma atypical lymphocytes, 246 acute leukemia, progression to, 508 nasal type see nasal type natural killer cell/T case studies, 33, 33, 259–270 myeloid cell factor 1 (MCL1), chronic cell lymphoma CD8 variant, 353–354, 363, 363 lymphocytic leukemia, 451 non-nasal, 377, 378 in childhood, 240 myeloid dendritic cell(s), 509–510 pathology, 380–381 chronic lymphocytic leukemia and, 450, 470, function, 509, 513–514 phenotypic studies, 338, 377, 381–382, 389, 470 myeloid marker profile, 509–510 390, 391, 393 classification, 4, 4–5 ontogeny, 513–514 treatment, 379 2007 revised classification, 245–246 myeloid dendritic cell dyscrasia, 508, 510 natural killer (NK)-like cells clinical presentation, 236–239, 237, 238, 239 myeloid dendritic cell leukemia, 510, 513 biology, 377–379 cytogenetics, 257 myeloid derived-cutaneous infiltrates, 507–539 function, 377–378 cytomorphology, 247, 252, 253 myeloid neoplasms, classification, 508, 508 hydroa vacciniforme-like-EBV-associated T cytotoxic phenotype, 260 myelomonocytic markers, definitions, 11 cell lymphoproliferative disease, 431

bindex 553 19 November 2015 7:21 PM 279mm×216mm 554 Index natural killer-like T cell lymphoma p16 deletions, natural killer cell/T cell acral pseudolymphomatous angiokeratomas of CD4+ variant, 384–385 lymphomas, 382 children, 67 case study, 393–396, 393–396 p16INK4a gene, diffuse large B cell lymphoma, adult T cell leukemia/lymphoma, 475, 478 cell of origin, 385 192 angioimmunoblastic T cell lymphoma, 488, clinical features, 384 9p21.3 deletion, diffuse large B cell lymphoma, 491 light microscopic findings, 384–385,395, 397 leg type, 191 atypical lymphocytic lobular panniculitis, 101, molecular studies, 385 p53 109, 110 phenotypic studies, 385, 394, 396 mantle cell lymphoma, 228 B cell chronic lymphocytic leukemia, 451, 457, differential diagnosis, 338 mycosis fungoides, 257 459, 461 NK cell lymphoma vs., 377 natural killer cell/T cell lymphomas, 382 blastic marginal zone lymphoma, 140 see also natural killer cell/T cell lymphomas pagetoid reticulosis, 241, 353 blastic plasmacytoid dendritic cell neoplasm, NCAM see CD56 markers morphology, 248 383, 399, 400 nervous system involvement, mycosis fungoides, panniculitic pseudolymphoma, 339 Burkitt’s lymphoma, 198 254 panniculitic T cell dyscrasias, 334 Castleman disease, 142 neutrophils panniculitis-like T cell lymphoma, subcutaneous CD30-negative large cell T cell lymphoma, anaplastic large cell lymphoma, 282 see subcutaneous panniculitis-like T cell 317–318 lymphomatoid papulosis, 276, 277 lymphoma cutaneous myeloid dendritic cell dyscrasia, NFAT see nuclear factor of activated T cells papular acrodermatitis of childhood see 513 (NFAT) Gianotti–Crosti syndrome Epstein–Barr virus+ cutaneous B cell nickel allergy, 37 papular pseudolymphoma, 60–61 lymphoproliferative disorder of the nitrogen mustards, mycosis fungoides, 15 papuloerythroderma of Ofuji, 239–240, 240 elderly, 420 NKp46, primary cutaneous aggressive paraffin-embedded tissue panels, 12 follicular dendritic cell sarcoma, 516 epidermotropic cytotoxic CD8+ T cell paraneoplastic dermatoses, chronic lymphocytic γ δ T cell lymphoma, 407–408, 412 lymphoma, 354 leukemia, 449 generalized eruptive histiocytosis, 515 NK/T cell lymphomas see natural killer cell/T parvovirus B19, 46, 55 histiocytic sarcoma, 516, 530 cell lymphomas Pautrier microabscess, mycosis fungoides, 246, HIV-related CD8 pseudolymphoma, 356 nodal follicular helper T cell lymphoma, 248, 249, 250, 353 Hodgkin lymphoma, 437, 441, 442, 445, 446 314–315 PAX5 hydroa vacciniforme-like-Epstein–Barr virus- nodal peripheral T cell lymphoma, 318 anaplastic large cell lymphoma, 284 associated T cell lymphoproliferative nodular amyloidosis, 143 definition, 11 disease, 417 nodular lymphocytic infiltrates, autoimmune Hodgkin lymphoma, 437, 446 hydroa vacciniforme-like lymphoma, 386 disease associated, 53–56 mantle cell lymphoma, 227–228 idiopathic erythroderma, 96 nodular lymphoid dermal infiltrates without mycosis fungoides, 256 indolent CD8 positive lymphoid proliferation atypica, 51–53 PCR see polymerase chain reaction (PCR) of the face, 355, 373, 374 nodular sclerosing Hodgkin lymphoma, 436, PD-1 see Programmed death-1 (PD-1) interdigitating dendritic cell sarcoma, 516 440, 445 pentostatin, cutaneous T cell lymphoma, 19 intravascular lymphoma, 219, 222 non-X histiocytopathy syndromes, 509 perforin, 351 juvenile xanthogranuloma, 514 NPM–ALK hybrid protein, anaplastic large cell anaplastic large cell lymphoma, 283 keratoderma-like T cell dyscrasia, 99–100, 131 lymphoma, 284, 302 indolent CD8 positive lymphoid proliferation Langerhans cell histiocytosis, 511 nuclear factor (NF)-kb of the face, 355, 373 Langerhans sarcoma, 512 chronic lymphocytic leukemia, 451 peripheral blood, adult T cell leukemia/ leukemia cutis, 509 Hodgkin lymphoma, 438 lymphoma, 480, 480 lichen planus, 51 nuclear factor of activated T cells (NFAT), 9–10 peripheral nervous system, mycosis fungoides, lupus erythematosus profundus, 337, 348 benign T cells, 317 254 lymphocyte-predominant Hodgkin definition, 9–10 peripheral T cell lymphoma, CD8-positive, 352, lymphoma, 437 mycosis fungoides, 256, 258, 270 352 lymphocytoma cutis, 65–66 primary cutaneous CD4+ small/medium- peripheral T cell lymphoma, not otherwise lymphomatoid papulosis, 277, 291, 292 sized pleomorphic T cell lymphoma, 317, specified, 312–333 mantle cell lymphoma, 226–227, 230, 232 331 case studies, 320–332, 320–332 marginal zone lymphoma, 136–137 types, 317 CD4+ variants, 312–333 mycosis fungoides, 254–256, 255, 256, 270 nummular eczema, 40–41 CD8+ variants, 353 natural killer cell/T cell lymphomas, 338, 377, CD30-negative cutaneous large T cell 381–382, 385, 389, 390, 391, 393, 394, 396 O10 see CD1a antigen lymphoma variant, 312, 312 pigmented purpuric dermatosis, 94, 106 Oct-2, lymphocyte-predominant Hodgkin cytogenetics, 318, 331 pityriasis lichenoides, 95–96 lymphoma, 437, 446 differential diagnosis, 318–319 pityriasis lichenoides chronica, 95, 104 OKT3 see CD3 antigen large cells, 315, 320, 324, 326, 327, 328 pityriasis lichenoides et varioliformis acuta, 95 OKT4 see CD4 antigen light microscopic findings, 315–316, 320, 322, precursor B cell lymphoblastic lymphoma, OKT6 see CD1a antigen 324, 326, 327, 328 196, 207 OKT11 see CD2 antigen molecular profile, 318 primary cutaneous CD4+ small/medium- oncogenes, marginal zone lymphoma, 138–139 pathogenesis, 318 sized pleomorphic T cell lymphoma, osteopontin, intravascular lymphoma, 219 pathology, 315–316 316–317, 321, 323 OTK1 see CD5 antigen phenotypic profile, 316–318 primary cutaneous follicle center lymphoma, prognosis, 315 171–172, 175, 177, 178, 180, 181, 183, 184, p14 deletions, natural killer cell/T cell subcutaneous fat involving, 339 193, 204 lymphomas, 382 Perry–Romberg syndrome, 54–55 Rosai–Dorfman disease, 514 p15 deletions, natural killer cell/T cell PGM1 see CD68 antigen T cell prolymphocytic leukemia, 453, 463, 464, lymphomas, 382 phenotypic profile/studies 465, 466

bindex 554 19 November 2015 7:21 PM 279mm×216mm Index 555

xanthoma disseminatum, 515 lupus erythematosus profundus, 64, 338 clinical presentation, 195, 195 Philadelphia chromosome, 508 plasmacytomas, 139 cytogenetics, 196, 210, 211, 212 photoadaption, polymorphous light eruption, 52 platelet-derived growth factor (PDGF), differential diagnosis, 197 photoallergic reactions, 40, 40 morphea, 55 hypodiploidy, 196, 211 polymorphous light eruption, 52 PLCG1 mutation, mycosis fungoides, 256 immunophenotype, 196, 207 photodynamic therapy (PDT) POEMS syndrome, 141 pathology, 195, 206 cutaneous T cell lymphoma, 16 case study, 160, 160 zonation pattern, 196 mycosis fungoides, 16 light microscopic findings, 141 prednisone phototherapy subcutaneous plasmacytomas, 142 cutaneous T cell lymphoma, 19 cutaneous T cell lymphoma, 16 polyacrylamide gel electrophoresis, 25 lymphomatoid granulomatosis, 502 mycosis fungoides development, 257 Polyclonal see CD3 antigen pre-Sézary syndrome, 96 phototoxicity, polymorphous light eruption, 52 polyclonal hypergammaglobulinemia, primary primary B cell lymphoma of leg type, 172 pigmented purpuric dermatosis (PPD), 92–94, cutaneous plasmacytosis, 66, 85 primary biliary cirrhosis, lichen planus-like 93 polymerase chain reaction (PCR), 23 eruptions, 48 case studies, 35, 35, 105, 105–108 B cell clonality, 28 primary cutaneous aggressive epidermotropic clinical features, 92, 92–93, 93 clonality analysis cytotoxic CD8+ T cell lymphoma, 352 drug-induced, 93 limitations, 27–28 angiocentricity, 353, 360 light microscopic findings, 94, 105 sensitivity, 27 case studies, 357, 357–359, 360, 360–362 molecular analysis, 27, 35, 94, 107–108, clonality determination design, 24 clinical features, 352 122–123, 128 clonality products detection, 24–25 differential diagnosis, 353 mycosis fungoides development, 93, 93 cutaneous T cell lymphoma, 25, 26 extracutaneous disease, 352 pathogenetic basis, 93 dual analysis, 26–27 histomorphology, 353, 357, 360, 362 phenotypic studies, 94, 106 false positives, 27–28 phenotype, 354 pilotropic mycosis fungoides, 98 indolent CD8 positive lymphoid proliferation primary cutaneous B cell lymphoma (PCBCL) pilotropic T cell dyscrasia, 97–98, 111, 111–112 of the face, 355 angioimmunoblastic T cell lymphoma, 487 pityriasiform drug eruptions, 39 lymphomatoid papulosis, 277, 300, 301 Epstein–Barr virus-positive, 193 pityriasis lichenoides, 94–96, 95 monoclonality, 26, 29, 30, 31, 32 molecular analysis, 27 light microscopic findings, 95, 102, 103, 104 mycosis fungoides, 256–257 primary cutaneous CD4+ small/medium-sized molecular profiles, 95–96, 120–121 poor-quality DNA template, 25 pleomorphic T cell lymphoma, 312–313, mycosis fungoides development, 95, 103 primary cutaneous follicle center lymphoma, 315 natural course, 95 172 B cell hyperplasia, 317 pathogenetic basis, 95 pseudoclonality, 27 case studies, 320–325, 320–325, 327, 327, 329, phenotypic studies, 95–96 results evaluation, 25, 26, 28 329–331 subtypes, 94 T cell receptor-γ gene, 24 CD30 positivity, 316, 319, 324, 324, 325, 327, pityriasis lichenoides chronica (PLC), 94, 94, TCR gene deletion, 28 327 95, 95 polymorphic post-transplant clinical presentation, 313, 313 case study, 33, 33, 34, 34, 102, 102–104 lymphoproliferative disease, 418 cytomorphology, 316, 320, 323, 324, 326 lesions, 95 polymorphous eruption of pregnancy, 41–42 differential diagnosis, 316, 318–319 light microscopy, 95, 103 polymorphous light eruption (PMLE), 52, 56 diffuse multifocal variant, 315 molecular analysis, 27, 33, 34, 119 clinical features, 51, 51–52 disseminated disease, 313 phenotypic studies, 95, 104 pathogenesis, 51–52 folliculotropism, 315–316 pityriasis lichenoides et varioliformis acuta polyneuropathy, osteosclerotic bone lesions/ light microscopic findings, 315–316, 320, 321 (PLEVA), 94, 95 and or organomegaly, endocrinopathy, molecular profile, 318 pityriasis lichenoides with no qualifier, 94 monoclonal gammopathy, and skin mycosis fungoides vs., 316 pityriasis rosea, 38, 39 lesions (POEMS) see POEMS syndrome nomenclature evolution, 319 differential diagnosis, 39–40 popcorn cell, 437 phenotypic profile, 316–317, 323 pityriasis rosea-like drug reaction, 40 post germinal center B cell lymphoproliferative pseudolymphoma vs., 318 plasmablastic lymphoma, 143, 418–419 disorders, 134–168 subcutaneous fat, extension into, 316, 320, AIDS patients, 418–419, 427, 427 post-transplant B cell lymphoma, 418 322, case study, 427, 427, 429 post-transplant lymphoproliferative disease 324, 326 EBV/HHV8 associated, 419, 423, 423–424 (PTLD), 417, 417–420 treatment, 313 post-transplant lymphoproliferative disease, case studies, 425, 425–426 primary cutaneous CD8+ T cell lymphomas 418–419, 423, 424, 427 categories, 418 classification, 352, 352–353 plasma cell(s) cell of origin, 418 clinical criteria, 352 immunocytoma, 136 differential diagnosis, 501 histomorphology, 353–354 mantle cell lymphoma, 226 Epstein–Barr virus, 417–418, 422 therapies, 353 marginal zone lymphoma, 136, 151, 152, 153, treatment, 418, 422 primary cutaneous diffuse large B cell lymphoma 154 pralatrexate see diffuse large B cell lymphoma morphea, 55 cutaneous T cell lymphoma, 19–20 primary cutaneous follicle center lymphoma plasma cell markers mycosis fungoides, 19–20 (PCFCL), 169–186, 170, 187, 189, 193 definitions, 10 Sézary syndrome, 20 case studies, 174–184, 174–184, 203, 203–205 paraffin-embedded tissue panels, 12 precursor B cell acute lymphoblastic leukemia CD30+ variant, 435 plasma cell orofacialis, 66 see precursor B cell lymphoblastic clinical features, 169 plasmacytic hyperplasia, 418 lymphoma cytogenetics, 172–173, 185, 191 plasmacytic marginal zone lymphoma see precursor B cell lymphoblastic lymphoma, diagnosis, 169 immunocytoma 195–197, 196 differential diagnosis, 438 plasmacytoid dendritic cells, 509, 510 case study, 206, 206–207 diffuse growth pattern, 169, 176, 179

bindex 555 19 November 2015 7:21 PM 279mm×216mm 556 Index primary cutaneous follicle (continued) PTEN gene, mycosis fungoides, 257 reversible lymphomas, 62 purine analogs, cutaneous T cell lymphoma, 19 reversible T cell dyscrasia, 59 germinal center-like foci, 190 pyogenic anaplastic large cell lymphoma, 282 Revised European–American Classification grading system, 170–171, 174, 176 of Lymphoid Neoplasms (REAL) intravascular localization, 219, 223, 223 QBEnd10 see CD34 antigen classification, 2, 2 light microscopic findings, 193 rheumatoid arthritis, 63 mixed cell type, 174, 174–175 radiation therapy, cutaneous T cell lymphoma, Richter’s transformation, 452 molecular studies, 27, 172 16 rituximab, lymphomatoid granulomatosis, 502 nodular growth pattern, 169, 176, 182 Rai staging system, chronic lymphocytic romidepsin, cutaneous T cell lymphoma, 19 pathogenesis, 172, 191, 192 leukemia, Rosai–Dorfman disease, 514, 524 pathology, 169–171, 174, 179, 182 449 phenotypic profile, 171–172, 175, 177, 178, Rappaport classification system, 1 S100 180, 181, 183, 184, 193, 204 RB1, mantle cell lymphoma, 228 interdigitating dendritic cell sarcoma, 516 prognosis, 169 Rb gene, natural killer cell/T cell lymphomas, Langerhans cell histiocytosis, 511, 518 pseudolymphomas vs., 169 382 Langerhans sarcoma, 512 spindle cell variants, 171 reactive CD30+ T cells, benign intravascular sarcomatoid anaplastic large cell lymphoma, therapy, 169 proliferations, 220 283, 305 primary cutaneous granulomatous T cell reactive clonal lymphomatoid dermatitis of case study, 305, 305–306 lymphoma, 353 memory and activated T cells, 62 differential diagnosis, 516 primary cutaneous plasmacytoma, 142–144, 143 reactive cutaneous lymphoid hyperplasia, 139 Schamberg’s disease, 93 differential diagnosis, 143, 144 reactive follicular mucinosis, 99 sclerodermatomyositis (SDM), 49 light microscopic findings, 143 reactive germinal centers sclerodermoid tissue reaction multiple myeloma and, 142–143 blastic marginal zone lymphoma, 190 Castleman disease, 141 pathogenesis, 144 marginal zone lymphoma, 136, 137, 145, 146, chronic graft-versus-host disease, 51 primary cutaneous plasmacytosis, 66–67, 85, 85 147, 148, 150, 155 seborrheic dermatitis, 41 primary cutaneous γ β T cell lymphoma see γ δ mycosis fungoides, 251 selectins, 9 T cell lymphoma reactive lymphoid hyperplasia, 37 self-healing reticulohistiocytosis, 511 primary extramedullary leukemia, 507 lymphocytoma cutis-like, 70, 70 senescent mummified cells, Hodgkin lymphoma, primary systemic plasmacytosis, 66, 142 marginal zone lymphoma, 136 436, 441 Programmed death-1 (PD-1), 192 peripheral T cell lymphoma, not otherwise Severity Weighted Assessment Tool, mycosis angioimmunoblastic T cell lymphoma, 488 specified, 318 fungoides, 236 blastic marginal zone lymphoma, 162 primary cutaneous follicle center lymphoma, Sézary cells, 243, 244, 245–246 cutaneous follicular helper T cell lymphoma, 315 169, 172, 177 Sézary syndrome, 237, 243, 243–251 definition, 10 reactive lymphomatoid conditions, 37, 38 CD4-positive γ δ variant, 406, 407 EBV+ B cell lymphoproliferative disease of the reactive lymphomatoid tissue classification, 4, 4–5 elderly, 428 case studies, 69–85 clinical features, 237, 243 follicular helper T cell lymphoma, 317 collagen vascular disease, 63–67 definition, 236 follicular helper T cells, 192 cutaneous B cell lymphoma mimicking, 59–88 diagnostic criteria, 243–244 primary cutaneous CD4+ small/medium-sized cutaneous T cell lymphoma mimicking, 59–88 differential diagnosis, 454 pleomorphic T cell lymphoma, 317, 318 REAL classification, 2, 2 ethnicity, 245 primary cutaneous follicle center lymphoma, red cell extravasation, T cell prolymphocytic genomic microarray analysis, 257 172, 192 leukemia, 462, 465 idiopathic erythroderma vs., 96 pseudolymphoma, 318 Reed–Sternberg cells, 440, 442 light microscopic findings, 244 Sézary syndrome, 244–245, 270 Hodgkin lymphoma, 436, 437 phenotypic profile, 256 promyelocyte, 533 nuclear factor-kb, 438 post-transplant, 419 promyelocytic leukemia gene translocation, Reed–Sternberg-like cells, Epstein–Barr- prognosis, 14, 243, 245 513, 532 associated mucocutaneous ulcer, 421 staging, 245, 245 pruritic folliculitis of pregnancy, 42 refractory anemia, 508 systemic therapy, 17 pruritic urticarial papules and plaques of refractory anemia with excess blasts-1, 508 treatment, 19 pregnancy (PUPPP), 41–42 refractory anemia with excess blasts-2, 508 2007 revised classification, 245–246 pruritus, patch stage mycosis fungoides, 236 refractory anemia with ringed sideroblasts, 508 variants, 243 PS!1 see CD3 antigen regulatory T cells single-stranded conformational polymorphism pseudolymphoma adult T cell leukemia/lymphoma, 475 (SSCP) analysis, 24–25 angiomatous variants, 67–68 chronic lymphocytic leukemia, 452 cutaneous T cell lymphoma, 24 CD4+ small/medium-sized pleomorphic T cutaneous lymphoid dyscrasia, 90 sinus histiocytosis with massive cell lymphoma vs., 318 cutaneous T cell lymphoma, 90 lymphadenopathy, 514, 524 CD8-positive, 355 renal involvement, mycosis fungoides, 254 siplizumab, cutaneous T cell lymphoma, 18 actinic reticuloid, as form of, 356 restricted T cell repertoire, 25, 28 Sjögren’s syndrome, lymphoepithelial-like drug-associated, 356, 370 collagen vascular disease, 63, 83, 83 lesions, 97 HIV-related, 356, 368 lupus erythematosus profundus, 64 skin-associated lymphoid tissue lymphoma development, 351 pigmented purpuric dermatosis, 94 (SALTOMA) see marginal zone differential diagnosis, 318 13-cis-retinoic acid see isotretinoin lymphoma primary cutaneous follicle center lymphoma retinoids, cutaneous T cell lymphoma, 17–18 skin biopsy, morphea, 55 vs., 169 topical application, 15–16 skin rash, epidermotropic marginal zone psoralen plus UVA (PUVA) reverse transcriptase in situ hybridization essays, lymphoma, 140 cutaneous T cell lymphoma, 16 13 small cell anaplastic large cell lymphoma, 282 side effects, 16 reversible lymphoid dyscrasia, 62 case studies, 286, 286

bindex 556 19 November 2015 7:21 PM 279mm×216mm Index 557

light microscopic findings, 281, 282, 286 syringotropism, primary cutaneous CD4+ case studies, 462–466, 462–466 phenotypic studies, 283, 286 small/medium-sized pleomorphic T cell CD4 and CD8 coexpression, 365, 365 small cell dominant lymphoma, 170 lymphoma, 315–316 CD8 variant, 355, 364, 364 small plaque parapsoriasis, 41, 91 systemic lupus erythematosus, 43, 45–46 case study, 364, 364 smoldering adult T cell leukemia/lymphoma, American College of Rheumatology criteria, histopathology, 355, 364, 365 474, 474, 477, 477, 478 46, 46 clinical features, 452–453, 453 Southern blot analysis, 23 histopathology, 50 cytogenetics, 453, 453–454, 467 SOX11, mantle cell lymphoma, 226–227 Kikuchi’s-like presentation, 63 cytoplasmic protrusions/blebs, 453 SP7 see CD3 antigen systemic plasmacytosis, 66, 142 differential diagnosis, 454 SPINK-2, primary cutaneous follicle center light microscopic findings, 453, 462, 464, 465 lymphoma, 192 t(14;18)(q32;q21) molecular studies, 468 spongiotic dermatitis, 37–40, 38, 38 blastic marginal zone lymphoma, 194–195 pathologic abnormalities, 453 Sry-related high-mobility group (SOX), 226 primary cutaneous follicle center lymphoma, phenotypic abnormalities, 453, 463, 464, 465, STAT, Hodgkin lymphoma, 438 172, 185 466 Stenotrophomonas maltophilia infection, 408 t(2;5)(p23;q35), anaplastic large cell lymphoma, T cell receptor (TCR), 404 Stevens–Johnson syndrome, 43 284, 302 rearrangement streak dyskeratosis, erythema multiforme, 43 t(11:14)(q13;q32), mantle cell lymphoma, 227, analysis, 24 stromal-1 signature, diffuse large B cell 233 anaplastic large cell lymphoma, 283 lymphoma, 191 t(12;21)(p12;q22), precursor B cell angioimmunoblastic T cell lymphoma, 486, stromal-2 signature, diffuse large B cell lymphoblastic lymphoma, 196, 210, 211 488–489 lymphoma, 191 T1 see CD5 antigen clonal, T cell pseudolymphoma, 62 stromal cell-derived factor 1-alpha see CXCR4 T3 see CD3 antigen cutaneous T cell lymphoma, 15 subacute cutaneous lupus erythematosus T6 see CD1a antigen lymphocytoma cutis, 66 (SCLE), 63 T11 see CD2 antigen mycosis fungoides, 26 clinical features, 49, 49 T199 see CD56 markers structure, 24, 404 drug-induced, 49, 49 Tac see CD25 antigen T cell receptor (TCR)-1, definition, 9 histopathology, 50, 50 TAFRO syndrome, 142 T cell receptor (TCR)-gamma 1, 9 immunofluorescent findings, 50 Tax, adult T cell leukemia/lymphoma, 475 T cell receptor (TCR) β, anaplastic large cell subcutaneous fat, nasal NK/T cell lymphoma, T-bet, angioimmunoblastic T cell lymphoma, lymphoma, 283–284 387 488 T cell receptor (TCR)-γ protein, 24 subcutaneous panniculitis-like T cell lymphoma, T cell(s) T-cell restricted intracellular antigen (TIA), 101, 334–350, 335, 404–406 γ δ see γ δ T cell(s) (under ‘gamma’) 351 case studies, 340–344, 340–344 helper see T helper cells hydroa vacciniforme-like-EBV CD4 phenotype, 337 lymphocytoma cutis, 65–66 lymphoproliferative disease, 417 in children, 335 paraffin-embedded tissue panels, 12 indolent CD8 positive lymphoid proliferation clinical features, 334–336, 335 reactive of the face, 355, 373 concomitant lupus erythematosus, 338 benign intravascular proliferations, 220 subcutaneous panniculitis-like T cell cytomorphology, 336, 341, 343, 346 marginal zone lymphoma, 136 lymphoma, 337 differential diagnosis, 334, 336–337, 337–339, regulatory see regulatory T cells type E lymphomatoid papulosis, 307 417 T cell acute lymphoblastic lymphoma, 454 T-cell rich angiomatoid polypoid dissemination, 335 T cell antibodies, definitions, 9–10 pseudolymphoma of the skin, 67 γ δ variant, 335–336 T cell chronic lymphocytic leukemia (T-CLL) T-cell-rich B cell lymphoma, 189, 190 hemophagocytic syndrome, 335 see T cell prolymphocytic leukemia techniques, 13 historical perspective, 334 (T-PLL) terminal deoxynucleotidyl transferase (TdT) light microscopic findings, 347–348 T cell clonal restriction granulocytic sarcoma, 209 lupus erythematosus profundus vs., 64, 334, cutaneous lymphoid dyscrasia, 89 precursor B cell lymphoblastic lymphoma, 336–337, 338, 342 cutaneous T cell lymphoma, 89 196, 207 molecular studies, 337 T cell clones, persistent, cutaneous lymphoid tetrasomy 8, 508, 536 morphology, 336–337, 340, 341, 343, 345, 346 dyscrasia, 89 Th1 cytokines, cutaneous T cell lymphoma, 14 phenotype, 337, 341, 342, 344, 347–348 T cell dyscrasias Th2 cytokines, cutaneous T cell lymphoma, 14 treatment, 336 drug-associated, 27, 28 T helper cells Sulzeberger–Garbe syndrome, 40 indolent, 91–92 chronic lymphocytic leukemia, 452 sunburn cells, 52 T cell intracellular antigen 1 (TIA-1) type 1 (Th1) cells, allergic contact Surveillance, Epidemiology and End Results anaplastic large cell lymphoma, 283 dermatitis, 37 (SEER) program, mycosis fungoides, 236 mycosis fungoides, 255 type 2 (Th2) cells syphilis, secondary, 48 NK/T cell lymphomas, 381 allergic contact dermatitis, 37 syringolymphoid hyperplasia with alopecia, subcutaneous panniculitis-like T cell vesicular mycosis fungoides, 242 96–97, 97 lymphoma, 337 thrombocytopenia, ascites, fever, reticulin case study, 115, 115 T cell leukemia/lymphoma 1 (TCL1a) fibrosis and organomegaly (TAFRO) differential diagnosis, 97 adult T cell leukemia/lymphoma, 475–476 syndrome, 66–67 epithelium hyperplasia, 97, 115, 116 chronic lymphocytic leukemia, 451 thymocyte selection-associated high-mobility light microscopy findings, 97, 115, 116 definition, 9 group box factor (TOX) see TOX molecular studies, 97 T cell prolymphocytic leukemia, 453, 454 TIA see T-cell restricted intracellular antigen phenotypic studies, 97 T cell post-transplant lymphoproliferative (TIA) syringotropic mycosis fungoides, 241, 251 disorders, 419–420 TIA-1 see T cell intracellular antigen 1 (TIA-1) syringotropic T cell lymphoma, case study, T cell prolymphocytic leukemia (T-PLL), tissue growth factor (TGF), morphea, 55 115, 115 452–454, 453 T lymphoblastic lymphoma, 197

bindex 557 19 November 2015 7:21 PM 279mm×216mm 558 Index

TNM classification tumid lupus erythematosus, 53–54 lymphomatoid granulomatosis vs., 501 mycosis fungoides, 4, 245–246, 246 tumor necrosis factor α (TNF-α), acute graft- pityriasis rosea, 39 Sézary syndrome, 4, 4–5, 245–246, 246 versus-host disease, 45 see also Epstein–Barr virus (EBV) To15, 10 tumor necrosis factor β (TNF-β), viral thymidine kinase (vTK), EBV-encoded, 422 Toll-like receptor (TLR) agonists, cutaneous T angioimmunoblastic T cell lymphoma, 489 viral thymidine kinase (vTK) assay, 13 cell lymphoma, 20 tumor-suppressor lung cancer 1 gene (TSLC1), VLA-4 (CD49d ), intravascular lymphoma, 219 Toll-like receptors (TLRs), 20 adult T cell leukemia/lymphoma, 475 vorinostat, 19 topical chemotherapy Twist 1, cutaneous T cell lymphoma, 14 VTH34.5 see CD5 antigen cutaneous T cell lymphoma, 15 type IV immune reaction mycosis fungoides, 15 cell-poor vacuolar interface dermatitis, 42 Weber–Christian disease, 337 topical corticosteroids polymorphous light eruption, 51–52 WHO classification, 2–7 cutaneous T cell lymphoma, 15 Tγ lymphocytes see natural killer (NK) cell(s) diffuse large B cell lymphoma, 188 mycosis fungoides, 15 myeloid neoplasms, 508, 508 total skin electron beam (TSEB) therapy, ultrastructural analysis, γ β T cell lymphoma, 408 natural killer cell/T cell lymphomas, 377 mycosis fungoides, 16 Tumours of Haematopoietic and Lymphoid Touton giant cells variable heavy (VH) segments, immunoglobulin Tissues, 5–7, 6–7 juvenile xanthogranuloma, 514, 524 heavy chain gene, 23 WHO-EORTC classification, 2–7, 3 xanthoma disseminatum, 514 vascular endothelial cell growth factor deficiencies, 3–4 TOX angioimmunoblastic T cell lymphoma, 489 diffuse large B cell lymphoma, 188 definition, 10 Castleman disease, 142 primary cutaneous T cell lymphoma, 351 mycosis fungoides, 256, 258, 269 diffuse large B cell lymphoma, leg type, 191 Sézary syndrome, 96 primary cutaneous CD4+ small/medium- vascular endothelial cell growth factor receptors, Wickham’s striae, lichen planus, 46, 47 sized pleomorphic T cell lymphoma, 317 diffuse large B cell lymphoma, leg type, 191 Woringer–Kolopp disease, 353 toxic epidermal necrolysis, 43 vascular leak syndrome (VLS), denileukin disseminated type see pagetoid reticulosis transforming growth factor receptor β (TRBRII), diftitox-induced, 18 Ketron–Goodman variant see pagetoid anaplastic large cell lymphoma, 284–285 V-D-J rearrangement, immunoglobulin H reticulosis transitional pre-B cells, 196 receptor, 23 Working Formulation classification, 1–2, 2 triamcinolone, mycosis fungoides, 15 vesicular mycosis fungoides, 239, 241–242, 266, World Health Organization (WHO) trimetrexate (TMTX), cutaneous T cell 266, 267 classification see WHO classification lymphoma, 19 viral-associated lymphomatoid dermatitis, 65 trisomy 3, marginal zone lymphoma, 138, 139 viral exanthem, 39 xanthoma disseminatum, 514–515 trisomy 3q, blastic marginal zone lymphoma, morbiliform, 45 140, 194 viral hypersensitivity reactions, 97 zanolimumab, 18 trisomy 8, 13 viral infection ZAP-70, anaplastic large cell lymphoma, 283 chronic myeloproliferative disease, 514, 533 angioimmunoblastic T cell lymphoma, Zoon’s balanitis circumscripta plasmacellularis, T cell prolymphocytic leukemia, 453 486–487 66, 67 tumid discoid lupus erythematosus, 63 erythema multiforme, 43 Zoon’s vulvitis, 67

bindex 558 19 November 2015 7:21 PM 279mm×216mm